| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.976 | 0.001 | 0.976 | DNA intercalator | |||
| 0.972 | 0.002 | 0.972 | Topoisomerase II inhibitor | |||
| 0.842 | 0.003 | 0.842 | Antimitotic | |||
| 0.781 | 0.004 | 0.781 | Platelet antagonist | 0.288 0.057 DBMET01513 | ||
| 0.754 | 0.002 | 0.754 | Topoisomerase I inhibitor | |||
| 0.734 | 0.005 | 0.734 | Hypoglycemic | 0.216 0.099 DBMET01513 | ||
| 0.681 | 0.003 | 0.681 | Alpha tubulin antagonist | |||
| 0.675 | 0.003 | 0.675 | Topoisomerase II alpha inhibitor | |||
| 0.666 | 0.004 | 0.666 | Cholinergic | |||
| 0.659 | 0.008 | 0.659 | Nootropic | |||
| 0.586 | 0.004 | 0.816 | Alpha-N-acetylglucosaminidase inhibitor | 0.816 0.002 DBMET00328 0.778 0.002 DBMET01513 0.652 0.003 DBMET00137 | DBMET00328 | |
| 0.586 | 0.005 | 0.586 | Platelet aggregation inhibitor | |||
| 0.561 | 0.013 | 0.647 | GABA C receptor rho-3 antagonist | 0.567 0.012 DBMET00328 0.647 0.004 DBMET01513 0.614 0.006 DBMET00137 | DBMET01513 | |
| 0.534 | 0.022 | 0.678 | 5 Hydroxytryptamine release stimulant | 0.477 0.031 DBMET00328 0.678 0.008 DBMET01513 0.537 0.022 DBMET00137 | DBMET01513 | |
| 0.486 | 0.04 | 0.536 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.533 0.021 DBMET00328 0.535 0.02 DBMET01513 0.536 0.02 DBMET00137 | DBMET00137 | |
| 0.474 | 0.041 | 0.622 | 5 Hydroxytryptamine release inhibitor | 0.441 0.056 DBMET00328 0.622 0.008 DBMET01513 0.496 0.034 DBMET00137 | DBMET01513 | |
| 0.442 | 0.041 | 0.661 | Aldehyde oxidase inhibitor | 0.586 0.021 DBMET00328 0.661 0.012 DBMET01513 0.57 0.023 DBMET00137 | DBMET01513 | |
| 0.462 | 0.077 | 0.651 | Caspase 9 stimulant | 0.446 0.085 DBMET00328 0.651 0.03 DBMET01513 0.468 0.074 DBMET00137 | DBMET01513 | |
| 0.369 | 0.022 | 0.391 | RNA-directed DNA polymerase inhibitor | 0.277 0.037 DBMET00328 0.391 0.019 DBMET01513 0.299 0.032 DBMET00137 | DBMET01513 | |
| 0.365 | 0.026 | 0.539 | Peroxidase inhibitor | 0.405 0.02 DBMET00328 0.539 0.007 DBMET01513 0.481 0.011 DBMET00137 | DBMET01513 | |
| 0.358 | 0.023 | 0.486 | 5 Hydroxytryptamine uptake stimulant | 0.388 0.016 DBMET00328 0.486 0.005 DBMET01513 0.427 0.01 DBMET00137 | DBMET01513 | |
| 0.321 | 0.006 | 0.491 | Ferrochelatase inhibitor | 0.367 0.004 DBMET00328 0.491 0.003 DBMET01513 0.398 0.004 DBMET00137 | DBMET01513 | |
| 0.335 | 0.02 | 0.48 | Tyrosine 3 hydroxylase inhibitor | 0.358 0.014 DBMET00328 0.48 0.004 DBMET01513 0.394 0.009 DBMET00137 | DBMET01513 | |
| 0.314 | 0.009 | 0.432 | UDP-glucose 4-epimerase inhibitor | 0.432 0.004 DBMET00328 0.402 0.005 DBMET01513 0.335 0.009 DBMET00137 | DBMET00328 | |
| 0.351 | 0.049 | 0.451 | Calcium channel activator | 0.344 0.054 DBMET00328 0.451 0.011 DBMET01513 0.38 0.033 DBMET00137 | DBMET01513 | |
| 0.351 | 0.052 | 0.351 | Spasmolytic | 0.256 0.089 DBMET01513 | ||
| 0.306 | 0.009 | 0.565 | GABA C receptor agonist | 0.365 0.006 DBMET00328 0.565 0.003 DBMET01513 0.526 0.003 DBMET00137 | DBMET01513 | |
| 0.324 | 0.036 | 0.367 | DNA synthesis inhibitor | 0.359 0.028 DBMET00328 0.367 0.027 DBMET01513 0.287 0.048 DBMET00137 | DBMET01513 | |
| 0.36 | 0.074 | 0.36 | Transcription factor NF kappa B inhibitor | 0.29 0.1 DBMET00328 0.334 0.082 DBMET01513 0.188 0.181 DBMET00137 | ||
| 0.313 | 0.038 | 0.313 | Nitric oxide antagonist | 0.157 0.09 DBMET00328 0.224 0.059 DBMET01513 | ||
| 0.366 | 0.093 | 0.51 | Histamine release inhibitor | 0.359 0.096 DBMET00328 0.51 0.025 DBMET01513 0.411 0.07 DBMET00137 | DBMET01513 | |
| 0.284 | 0.016 | 0.344 | Nitric-oxide synthase stimulant | 0.263 0.025 DBMET00328 0.344 0.005 DBMET01513 0.294 0.013 DBMET00137 | DBMET01513 | |
| 0.333 | 0.072 | 0.531 | Cholesterol antagonist | 0.318 0.08 DBMET00328 0.531 0.028 DBMET01513 0.333 0.072 DBMET00137 | DBMET01513 | |
| 0.336 | 0.08 | 0.451 | Vasodilator, peripheral | 0.221 0.153 DBMET00328 0.451 0.04 DBMET01513 0.27 0.113 DBMET00137 | DBMET01513 | |
| 0.261 | 0.005 | 0.261 | Beta tubulin antagonist | |||
| 0.3 | 0.048 | 0.3 | Pyruvate kinase inhibitor | 0.192 0.086 DBMET00328 0.192 0.086 DBMET01513 0.138 0.126 DBMET00137 | ||
| 0.26 | 0.01 | 0.312 | GABA C receptor rho-2 antagonist | 0.237 0.014 DBMET00328 0.312 0.005 DBMET01513 0.273 0.008 DBMET00137 | DBMET01513 | |
| 0.262 | 0.019 | 0.445 | Succinate dehydrogenase inhibitor | 0.445 0.004 DBMET00328 0.405 0.004 DBMET01513 0.317 0.008 DBMET00137 | DBMET00328 | |
| 0.252 | 0.009 | 0.348 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.211 0.014 DBMET00328 0.348 0.005 DBMET01513 0.273 0.008 DBMET00137 | DBMET01513 | |
| 0.252 | 0.015 | 0.274 | 5 Hydroxytryptamine 3E antagonist | 0.263 0.011 DBMET00328 0.257 0.013 DBMET01513 0.274 0.008 DBMET00137 | DBMET00137 | |
| 0.242 | 0.007 | 0.447 | Triose-phosphate isomerase inhibitor | 0.423 0.003 DBMET00328 0.447 0.003 DBMET01513 0.296 0.005 DBMET00137 | DBMET01513 | |
| 0.243 | 0.017 | 0.243 | Alkylator | 0.137 0.054 DBMET00328 0.185 0.031 DBMET01513 0.108 0.08 DBMET00137 | ||
| 0.232 | 0.011 | 0.246 | Arachidonic acid antagonist | 0.212 0.023 DBMET00328 0.246 0.006 DBMET01513 0.219 0.018 DBMET00137 | DBMET01513 | |
| 0.225 | 0.009 | 0.297 | NADH dehydrogenase inhibitor | 0.192 0.011 DBMET00328 0.297 0.007 DBMET01513 0.251 0.008 DBMET00137 | DBMET01513 | |
| 0.223 | 0.009 | 0.307 | GABA C receptor antagonist | 0.212 0.011 DBMET00328 0.307 0.004 DBMET01513 0.257 0.006 DBMET00137 | DBMET01513 | |
| 0.286 | 0.072 | 0.286 | Hypoxia-inducible factor 1 alpha inhibitor | 0.206 0.145 DBMET00328 0.231 0.118 DBMET01513 | ||
| 0.24 | 0.028 | 0.24 | Acetylcholine M1 receptor antagonist | 0.147 0.078 DBMET01513 | ||
| 0.272 | 0.064 | 0.405 | Interleukin agonist | 0.246 0.081 DBMET00328 0.405 0.018 DBMET01513 0.288 0.054 DBMET00137 | DBMET01513 | |
| 0.231 | 0.032 | 0.265 | Interferon gamma antagonist | 0.173 0.055 DBMET00328 0.265 0.026 DBMET01513 0.186 0.047 DBMET00137 | DBMET01513 | |
| 0.23 | 0.036 | 0.23 | Histone acetyltransferase inhibitor | 0.175 0.106 DBMET01513 0.161 0.125 DBMET00137 | ||
| 0.26 | 0.068 | 0.571 | Superoxide dismutase inhibitor | 0.571 0.008 DBMET00328 0.474 0.015 DBMET01513 0.378 0.031 DBMET00137 | DBMET00328 | |
| 0.253 | 0.062 | 0.3 | Cyclic AMP phosphodiesterase inhibitor | 0.159 0.138 DBMET00328 0.3 0.042 DBMET01513 0.202 0.092 DBMET00137 | DBMET01513 | |
| 0.194 | 0.004 | 0.218 | Ca2+-transporting ATPase inhibitor | 0.183 0.006 DBMET00328 0.218 0.002 DBMET01513 0.192 0.004 DBMET00137 | DBMET01513 | |
| 0.204 | 0.014 | 0.356 | Adenylate kinase inhibitor | 0.356 0.004 DBMET00328 0.336 0.005 DBMET01513 0.277 0.008 DBMET00137 | DBMET00328 | |
| 0.236 | 0.047 | 0.298 | Neurotrophic factor enhancer | 0.216 0.062 DBMET00328 0.298 0.018 DBMET01513 0.233 0.049 DBMET00137 | DBMET01513 | |
| 0.235 | 0.047 | 0.235 | P-glycoprotein inhibitor | 0.234 0.047 DBMET01513 | ||
| 0.196 | 0.009 | 0.255 | GABA C receptor rho-1 antagonist | 0.184 0.011 DBMET00328 0.255 0.004 DBMET01513 0.223 0.005 DBMET00137 | DBMET01513 | |
| 0.258 | 0.07 | 0.338 | Gastrin inhibitor | 0.239 0.092 DBMET00328 0.338 0.014 DBMET01513 0.275 0.053 DBMET00137 | DBMET01513 | |
| 0.24 | 0.055 | 0.434 | Anesthetic general | 0.247 0.051 DBMET00328 0.434 0.013 DBMET01513 0.256 0.048 DBMET00137 | DBMET01513 | |
| 0.196 | 0.013 | 0.49 | Porphobilinogen synthase inhibitor | 0.308 0.005 DBMET00328 0.49 0.003 DBMET01513 0.287 0.005 DBMET00137 | DBMET01513 | |
| 0.194 | 0.012 | 0.273 | Phosphofructokinase-1 inhibitor | 0.273 0.006 DBMET00328 0.256 0.007 DBMET01513 0.218 0.009 DBMET00137 | DBMET00328 | |
| 0.207 | 0.027 | 0.277 | Mannose-6-phosphate isomerase inhibitor | 0.277 0.008 DBMET00328 0.229 0.018 DBMET01513 0.215 0.023 DBMET00137 | DBMET00328 | |
| 0.19 | 0.01 | 0.19 | DNA repair enzyme inhibitor | 0.107 0.103 DBMET00328 0.142 0.039 DBMET01513 0.126 0.061 DBMET00137 | ||
| 0.196 | 0.025 | 0.258 | Cystathionine beta-synthase inhibitor | 0.161 0.036 DBMET00328 0.258 0.014 DBMET01513 0.226 0.019 DBMET00137 | DBMET01513 | |
| 0.178 | 0.008 | 0.178 | Acetylcholine muscarinic agonist | 0.058 0.036 DBMET01513 | ||
| 0.196 | 0.029 | 0.601 | Aldehyde dehydrogenase inhibitor | 0.601 0.004 DBMET00328 0.304 0.011 DBMET01513 0.162 0.041 DBMET00137 | DBMET00328 | |
| 0.223 | 0.056 | 0.347 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.22 0.058 DBMET00328 0.347 0.013 DBMET01513 0.269 0.034 DBMET00137 | DBMET01513 | |
| 0.187 | 0.02 | 0.236 | Adenylate cyclase stimulant | 0.177 0.029 DBMET00328 0.236 0.005 DBMET01513 0.195 0.016 DBMET00137 | DBMET01513 | |
| 0.27 | 0.115 | 0.383 | Vasodilator, coronary | 0.27 0.114 DBMET00328 0.383 0.041 DBMET01513 0.278 0.107 DBMET00137 | DBMET01513 | |
| 0.174 | 0.021 | 0.218 | Mucolytic | 0.134 0.043 DBMET00328 0.218 0.01 DBMET01513 0.145 0.036 DBMET00137 | DBMET01513 | |
| 0.172 | 0.02 | 0.172 | Acetylcholine agonist | |||
| 0.197 | 0.045 | 0.285 | Amylase inhibitor | 0.285 0.02 DBMET00328 0.269 0.023 DBMET01513 0.188 0.048 DBMET00137 | DBMET00328 | |
| 0.157 | 0.007 | 0.157 | Acetylcholine M1 receptor agonist | 0.041 0.032 DBMET01513 | ||
| 0.166 | 0.018 | 0.254 | Creatine kinase inhibitor | 0.186 0.013 DBMET00328 0.254 0.005 DBMET01513 0.214 0.009 DBMET00137 | DBMET01513 | |
| 0.182 | 0.035 | 0.215 | CF transmembrane conductance regulator agonist | 0.177 0.039 DBMET00328 0.215 0.015 DBMET01513 0.188 0.029 DBMET00137 | DBMET01513 | |
| 0.156 | 0.009 | 0.863 | Alcohol oxidase inhibitor | 0.853 0.002 DBMET00328 0.863 0.002 DBMET01513 0.359 0.004 DBMET00137 | DBMET01513 | |
| 0.145 | 0.005 | 0.145 | Topoisomerase II beta inhibitor | 0.086 0.012 DBMET01513 0.055 0.027 DBMET00137 | ||
| 0.146 | 0.01 | 0.265 | Biliverdin reductase inhibitor | 0.162 0.008 DBMET00328 0.265 0.004 DBMET01513 0.208 0.005 DBMET00137 | DBMET01513 | |
| 0.166 | 0.03 | 0.215 | Microtubule formation inhibitor | 0.167 0.03 DBMET00328 0.215 0.017 DBMET01513 0.144 0.041 DBMET00137 | DBMET01513 | |
| 0.142 | 0.009 | 0.235 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.235 0.005 DBMET00328 0.174 0.008 DBMET01513 0.156 0.008 DBMET00137 | DBMET00328 | |
| 0.142 | 0.01 | 0.224 | Acyl-CoA dehydrogenase inhibitor | 0.172 0.007 DBMET00328 0.224 0.004 DBMET01513 0.192 0.006 DBMET00137 | DBMET01513 | |
| 0.142 | 0.012 | 0.261 | Carbamoyl phosphate synthetase inhibitor | 0.162 0.01 DBMET00328 0.261 0.005 DBMET01513 0.212 0.007 DBMET00137 | DBMET01513 | |
| 0.142 | 0.014 | 0.142 | Lanosterol 14 alpha demethylase inhibitor | 0.115 0.035 DBMET00328 0.138 0.017 DBMET01513 0.131 0.021 DBMET00137 | ||
| 0.152 | 0.026 | 0.152 | Caspase 3 inhibitor | 0.148 0.029 DBMET00328 0.146 0.031 DBMET01513 0.103 0.086 DBMET00137 | ||
| 0.154 | 0.029 | 0.235 | Photosensitizer | 0.154 0.029 DBMET00328 0.235 0.007 DBMET01513 0.155 0.028 DBMET00137 | DBMET01513 | |
| 0.153 | 0.029 | 0.198 | TRPA1 agonist | 0.198 0.011 DBMET00328 0.183 0.015 DBMET01513 0.131 0.047 DBMET00137 | DBMET00328 | |
| 0.16 | 0.038 | 0.16 | Acetylcholine muscarinic antagonist | 0.107 0.082 DBMET01513 | ||
| 0.153 | 0.034 | 0.21 | Expectorant | 0.105 0.063 DBMET00328 0.21 0.018 DBMET01513 0.116 0.054 DBMET00137 | DBMET01513 | |
| 0.247 | 0.128 | 0.356 | Antithrombotic | 0.301 0.087 DBMET00328 0.356 0.062 DBMET01513 0.215 0.159 DBMET00137 | DBMET01513 | |
| 0.129 | 0.01 | 0.201 | Glycine receptor agonist | 0.117 0.014 DBMET00328 0.201 0.004 DBMET01513 0.128 0.011 DBMET00137 | DBMET01513 | |
| 0.152 | 0.034 | 0.205 | 5 Hydroxytryptamine 3A agonist | 0.141 0.04 DBMET00328 0.163 0.029 DBMET01513 0.205 0.014 DBMET00137 | DBMET00137 | |
| 0.166 | 0.051 | 0.231 | Cell wall synthesis inhibitor | 0.148 0.068 DBMET00328 0.231 0.02 DBMET01513 0.165 0.051 DBMET00137 | DBMET01513 | |
| 0.139 | 0.024 | 0.171 | Anabolic | 0.144 0.021 DBMET00328 0.171 0.009 DBMET01513 0.147 0.019 DBMET00137 | DBMET01513 | |
| 0.231 | 0.116 | 0.322 | Insulysin inhibitor | 0.265 0.083 DBMET00328 0.322 0.046 DBMET01513 0.297 0.06 DBMET00137 | DBMET01513 | |
| 0.129 | 0.014 | 0.144 | Glycine receptor antagonist | 0.117 0.02 DBMET00328 0.144 0.009 DBMET01513 0.128 0.014 DBMET00137 | DBMET01513 | |
| 0.159 | 0.048 | 0.159 | Cholinergic antagonist | 0.102 0.093 DBMET01513 | ||
| 0.155 | 0.044 | 0.232 | Cyclooxygenase 3 inhibitor | 0.137 0.06 DBMET00328 0.232 0.011 DBMET01513 0.157 0.042 DBMET00137 | DBMET01513 | |
| 0.138 | 0.029 | 0.195 | DOPA decarboxylase inhibitor | 0.162 0.016 DBMET00328 0.195 0.007 DBMET01513 0.177 0.011 DBMET00137 | DBMET01513 | |
| 0.129 | 0.02 | 0.266 | Glutamate dehydrogenase inhibitor | 0.17 0.013 DBMET00328 0.266 0.007 DBMET01513 0.19 0.011 DBMET00137 | DBMET01513 | |
| 0.154 | 0.048 | 0.154 | Acetylcholine antagonist | 0.098 0.095 DBMET01513 | ||
| 0.125 | 0.019 | 0.165 | Glutamate release inhibitor | 0.12 0.022 DBMET00328 0.165 0.007 DBMET01513 0.137 0.014 DBMET00137 | DBMET01513 | |
| 0.123 | 0.017 | 0.123 | Acetylcholine M4 receptor antagonist | 0.08 0.046 DBMET01513 | ||
| 0.171 | 0.069 | 0.236 | ATPase inhibitor | 0.209 0.031 DBMET00328 0.236 0.018 DBMET01513 0.18 0.058 DBMET00137 | DBMET01513 | |
| 0.215 | 0.114 | 0.257 | 5 Hydroxytryptamine 1E antagonist | 0.223 0.105 DBMET00328 0.244 0.081 DBMET01513 0.257 0.067 DBMET00137 | DBMET00137 | |
| 0.13 | 0.029 | 0.247 | Electrolyte absorption antagonist | 0.16 0.016 DBMET00328 0.247 0.005 DBMET01513 0.174 0.012 DBMET00137 | DBMET01513 | |
| 0.104 | 0.004 | 0.144 | Glucose-6-phosphate isomerase inhibitor | 0.144 0.003 DBMET00328 0.13 0.003 DBMET01513 0.117 0.004 DBMET00137 | DBMET00328 | |
| 0.164 | 0.065 | 0.216 | Melanin inhibitor | 0.21 0.037 DBMET00328 0.216 0.035 DBMET01513 0.164 0.065 DBMET00137 | DBMET01513 | |
| 0.171 | 0.072 | 0.234 | Phospholipase C inhibitor | 0.184 0.057 DBMET00328 0.234 0.029 DBMET01513 0.193 0.049 DBMET00137 | DBMET01513 | |
| 0.117 | 0.018 | 0.171 | Granulocyte macrophage colony stimulating factor agonist | 0.144 0.006 DBMET00328 0.171 0.004 DBMET01513 0.141 0.007 DBMET00137 | DBMET01513 | |
| 0.103 | 0.005 | 0.103 | Lipocortins synthesis agonist | 0.081 0.013 DBMET01513 | ||
| 0.257 | 0.159 | 0.257 | 15-Lipoxygenase inhibitor | 0.24 0.173 DBMET01513 | ||
| 0.138 | 0.043 | 0.218 | Aminopeptidase B inhibitor | 0.212 0.019 DBMET00328 0.218 0.017 DBMET01513 0.181 0.026 DBMET00137 | DBMET01513 | |
| 0.109 | 0.017 | 0.278 | Argininosuccinate synthase inhibitor | 0.278 0.004 DBMET00328 0.245 0.005 DBMET01513 0.171 0.01 DBMET00137 | DBMET00328 | |
| 0.146 | 0.055 | 0.167 | Heat shock protein 70 antagonist | 0.145 0.059 DBMET00328 0.167 0.02 DBMET01513 0.157 0.033 DBMET00137 | DBMET01513 | |
| 0.123 | 0.036 | 0.22 | Prolactin inhibitor | 0.182 0.012 DBMET00328 0.22 0.006 DBMET01513 0.163 0.017 DBMET00137 | DBMET01513 | |
| 0.257 | 0.17 | 0.31 | Antibacterial | 0.263 0.165 DBMET00328 0.31 0.128 DBMET01513 | DBMET01513 | |
| 0.128 | 0.04 | 0.128 | Bronchodilator | |||
| 0.111 | 0.024 | 0.277 | Glutamate decarboxylase inhibitor | 0.244 0.005 DBMET00328 0.277 0.004 DBMET01513 0.178 0.009 DBMET00137 | DBMET01513 | |
| 0.097 | 0.01 | 0.153 | Exportin-1 inhibitor | 0.117 0.005 DBMET00328 0.153 0.003 DBMET01513 0.113 0.005 DBMET00137 | DBMET01513 | |
| 0.097 | 0.012 | 0.145 | Glutamate (mGluR6) antagonist | 0.1 0.01 DBMET00328 0.145 0.004 DBMET01513 0.114 0.007 DBMET00137 | DBMET01513 | |
| 0.108 | 0.024 | 0.116 | Na+ K+ transporting ATPase inhibitor | 0.116 0.019 DBMET00328 0.115 0.019 DBMET01513 0.105 0.027 DBMET00137 | DBMET00328 | |
| 0.139 | 0.055 | 0.223 | Cathepsin H inhibitor | 0.223 0.017 DBMET00328 0.188 0.026 DBMET01513 0.168 0.035 DBMET00137 | DBMET00328 | |
| 0.135 | 0.053 | 0.211 | Cholesterol synthesis inhibitor | 0.186 0.03 DBMET00328 0.211 0.024 DBMET01513 0.14 0.05 DBMET00137 | DBMET01513 | |
| 0.102 | 0.022 | 0.151 | Estrogen-related receptor beta agonist | 0.106 0.018 DBMET00328 0.151 0.004 DBMET01513 0.114 0.013 DBMET00137 | DBMET01513 | |
| 0.097 | 0.017 | 0.134 | Purinergic P2X1 antagonist | 0.117 0.012 DBMET00328 0.134 0.009 DBMET01513 0.123 0.011 DBMET00137 | DBMET01513 | |
| 0.089 | 0.009 | 0.089 | Epithelial sodium channel blocker | 0.06 0.028 DBMET01513 0.063 0.025 DBMET00137 | ||
| 0.123 | 0.043 | 0.162 | Acetylcholine release stimulant | 0.12 0.048 DBMET00328 0.162 0.01 DBMET01513 0.139 0.024 DBMET00137 | DBMET01513 | |
| 0.148 | 0.07 | 0.254 | Protein kinase stimulant | 0.127 0.086 DBMET00328 0.254 0.025 DBMET01513 0.151 0.068 DBMET00137 | DBMET01513 | |
| 0.088 | 0.011 | 0.193 | Aconitate hydratase inhibitor | 0.106 0.007 DBMET00328 0.193 0.003 DBMET01513 0.155 0.004 DBMET00137 | DBMET01513 | |
| 0.102 | 0.027 | 0.178 | Aminopeptidase I inhibitor | 0.125 0.018 DBMET00328 0.178 0.009 DBMET01513 0.14 0.014 DBMET00137 | DBMET01513 | |
| 0.104 | 0.029 | 0.108 | mTOR complex 2 inhibitor | 0.091 0.046 DBMET00328 0.106 0.026 DBMET01513 0.108 0.025 DBMET00137 | DBMET00137 | |
| 0.11 | 0.035 | 0.266 | Catalase inhibitor | 0.244 0.009 DBMET00328 0.266 0.008 DBMET01513 0.167 0.022 DBMET00137 | DBMET01513 | |
| 0.09 | 0.018 | 0.12 | Glutamate (mGluR7) antagonist | 0.099 0.011 DBMET00328 0.12 0.005 DBMET01513 0.112 0.006 DBMET00137 | DBMET01513 | |
| 0.133 | 0.061 | 0.161 | Vanilloid 1 agonist | 0.131 0.065 DBMET00328 0.161 0.029 DBMET01513 0.137 0.054 DBMET00137 | DBMET01513 | |
| 0.108 | 0.036 | 0.152 | Ornithine decarboxylase inhibitor | 0.13 0.019 DBMET00328 0.152 0.01 DBMET01513 0.104 0.04 DBMET00137 | DBMET01513 | |
| 0.144 | 0.073 | 0.197 | Sphingosine 1-phosphate receptor 5 antagonist | 0.15 0.061 DBMET00328 0.197 0.013 DBMET01513 0.169 0.034 DBMET00137 | DBMET01513 | |
| 0.134 | 0.064 | 0.217 | Toll-Like receptor 2 antagonist | 0.158 0.047 DBMET00328 0.217 0.017 DBMET01513 0.158 0.047 DBMET00137 | DBMET01513 | |
| 0.091 | 0.021 | 0.112 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.093 0.019 DBMET00328 0.112 0.008 DBMET01513 0.106 0.01 DBMET00137 | DBMET01513 | |
| 0.135 | 0.065 | 0.181 | Sphingosine 1-phosphate receptor 2 antagonist | 0.138 0.059 DBMET00328 0.181 0.014 DBMET01513 0.155 0.034 DBMET00137 | DBMET01513 | |
| 0.186 | 0.119 | 0.207 | Peptidyltransferase inhibitor | 0.207 0.09 DBMET01513 | DBMET01513 | |
| 0.09 | 0.024 | 0.09 | Acetylcholine M2 receptor antagonist | |||
| 0.113 | 0.047 | 0.132 | Sphingomyelinase inhibitor | 0.102 0.058 DBMET00328 0.132 0.033 DBMET01513 0.127 0.036 DBMET00137 | DBMET01513 | |
| 0.084 | 0.018 | 0.084 | Thromboxane antagonist | 0.057 0.034 DBMET01513 | ||
| 0.094 | 0.029 | 0.221 | Phenylalanine 4-hydroxylase inhibitor | 0.114 0.02 DBMET00328 0.221 0.005 DBMET01513 0.156 0.011 DBMET00137 | DBMET01513 | |
| 0.156 | 0.091 | 0.287 | 3C-like protease (Human coronavirus) inhibitor | 0.287 0.014 DBMET00328 0.242 0.031 DBMET01513 0.219 0.042 DBMET00137 | DBMET00328 | |
| 0.087 | 0.022 | 0.113 | Protease 3C (Human rhinovirus) inhibitor | 0.113 0.011 DBMET00328 0.104 0.014 DBMET01513 0.082 0.026 DBMET00137 | DBMET00328 | |
| 0.147 | 0.082 | 0.2 | Hexokinase inhibitor | 0.2 0.035 DBMET00328 0.183 0.047 DBMET01513 0.162 0.066 DBMET00137 | DBMET00328 | |
| 0.09 | 0.026 | 0.115 | Vanilloid 4 agonist | 0.098 0.019 DBMET00328 0.115 0.009 DBMET01513 0.109 0.011 DBMET00137 | DBMET01513 | |
| 0.077 | 0.013 | 0.11 | Alpha-mannosidase inhibitor | 0.11 0.005 DBMET00328 0.091 0.008 DBMET01513 0.083 0.01 DBMET00137 | DBMET00328 | |
| 0.096 | 0.033 | 0.267 | Histidine decarboxylase inhibitor | 0.156 0.019 DBMET00328 0.267 0.008 DBMET01513 0.189 0.014 DBMET00137 | DBMET01513 | |
| 0.098 | 0.037 | 0.134 | CYP2A6 inhibitor | 0.127 0.024 DBMET00328 0.134 0.021 DBMET01513 0.124 0.025 DBMET00137 | DBMET01513 | |
| 0.096 | 0.035 | 0.12 | D-Ala-D-Ala ligase inhibitor | 0.099 0.03 DBMET00328 0.12 0.014 DBMET01513 0.115 0.016 DBMET00137 | DBMET01513 | |
| 0.077 | 0.017 | 0.077 | Thromboxane A2 antagonist | 0.056 0.031 DBMET01513 | ||
| 0.113 | 0.053 | 0.158 | Carbonic anhydrase XV inhibitor | 0.114 0.052 DBMET00328 0.158 0.028 DBMET01513 0.15 0.031 DBMET00137 | DBMET01513 | |
| 0.093 | 0.033 | 0.137 | GABA aminotransferase inhibitor | 0.102 0.025 DBMET00328 0.137 0.01 DBMET01513 0.11 0.021 DBMET00137 | DBMET01513 | |
| 0.071 | 0.012 | 0.108 | Adenylate cyclase 1 inhibitor | 0.065 0.014 DBMET00328 0.108 0.004 DBMET01513 0.088 0.005 DBMET00137 | DBMET01513 | |
| 0.066 | 0.007 | 0.07 | Guanylate cyclase inhibitor | 0.058 0.014 DBMET00328 0.07 0.005 DBMET01513 0.068 0.005 DBMET00137 | DBMET01513 | |
| 0.063 | 0.005 | 0.063 | Purinergic P2Y12 antagonist | |||
| 0.141 | 0.083 | 0.204 | Cytidine deaminase inhibitor | 0.114 0.107 DBMET00328 0.204 0.046 DBMET01513 0.132 0.089 DBMET00137 | DBMET01513 | |
| 0.071 | 0.013 | 0.097 | Pregnane X receptor antagonist | 0.08 0.006 DBMET00328 0.097 0.004 DBMET01513 0.078 0.007 DBMET00137 | DBMET01513 | |
| 0.078 | 0.021 | 0.078 | Acetyl-CoA transferase inhibitor | |||
| 0.152 | 0.096 | 0.216 | Neurotensin receptor agonist | 0.162 0.075 DBMET00328 0.216 0.028 DBMET01513 0.179 0.05 DBMET00137 | DBMET01513 | |
| 0.087 | 0.03 | 0.117 | GABA B receptor agonist | 0.087 0.03 DBMET00328 0.117 0.008 DBMET01513 0.101 0.016 DBMET00137 | DBMET01513 | |
| 0.079 | 0.025 | 0.079 | Acetylcholine M5 receptor antagonist | |||
| 0.184 | 0.13 | 0.276 | DNA damaging | 0.276 0.067 DBMET01513 | DBMET01513 | |
| 0.083 | 0.03 | 0.114 | Phospholipase D inhibitor | 0.091 0.021 DBMET00328 0.114 0.008 DBMET01513 0.108 0.011 DBMET00137 | DBMET01513 | |
| 0.104 | 0.052 | 0.136 | Glutamate (mGluR7) agonist | 0.104 0.051 DBMET00328 0.136 0.018 DBMET01513 0.131 0.021 DBMET00137 | DBMET01513 | |
| 0.121 | 0.069 | 0.169 | Sphingosine 1-phosphate receptor 4 antagonist | 0.131 0.055 DBMET00328 0.169 0.02 DBMET01513 0.138 0.045 DBMET00137 | DBMET01513 | |
| 0.064 | 0.014 | 0.096 | Mannosidase inhibitor | 0.096 0.006 DBMET00328 0.078 0.009 DBMET01513 0.072 0.011 DBMET00137 | DBMET00328 | |
| 0.082 | 0.033 | 0.123 | Acetylcholine M5 receptor agonist | 0.081 0.033 DBMET00328 0.123 0.01 DBMET01513 0.106 0.017 DBMET00137 | DBMET01513 | |
| 0.054 | 0.006 | 0.054 | Kynurenine 3 monooxygenase inhibitor | 0.037 0.011 DBMET01513 | ||
| 0.058 | 0.01 | 0.058 | Acetyl-CoA transferase 1 inhibitor | |||
| 0.056 | 0.009 | 0.076 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.06 0.007 DBMET00328 0.076 0.004 DBMET01513 0.072 0.004 DBMET00137 | DBMET01513 | |
| 0.064 | 0.017 | 0.069 | Squalene epoxidase inhibitor | 0.059 0.021 DBMET00328 0.069 0.014 DBMET01513 0.063 0.018 DBMET00137 | DBMET01513 | |
| 0.104 | 0.058 | 0.159 | Carbonic anhydrase III inhibitor | 0.096 0.067 DBMET00328 0.159 0.025 DBMET01513 0.129 0.039 DBMET00137 | DBMET01513 | |
| 0.134 | 0.088 | 0.172 | Pregnane X receptor agonist | 0.146 0.061 DBMET00328 0.172 0.024 DBMET01513 0.152 0.05 DBMET00137 | DBMET01513 | |
| 0.056 | 0.011 | 0.164 | Fumarate hydratase inhibitor | 0.074 0.008 DBMET00328 0.164 0.004 DBMET01513 0.094 0.006 DBMET00137 | DBMET01513 | |
| 0.07 | 0.025 | 0.17 | Ornithine carbamoyltransferase inhibitor | 0.17 0.008 DBMET00328 0.155 0.009 DBMET01513 0.11 0.014 DBMET00137 | DBMET00328 | |
| 0.095 | 0.05 | 0.123 | Histamine N-methyltransferase inhibitor | 0.091 0.054 DBMET00328 0.12 0.029 DBMET01513 0.123 0.028 DBMET00137 | DBMET00137 | |
| 0.058 | 0.013 | 0.103 | Dopamine D5 agonist | 0.06 0.012 DBMET00328 0.103 0.004 DBMET01513 0.078 0.006 DBMET00137 | DBMET01513 | |
| 0.086 | 0.043 | 0.126 | Interferon agonist | 0.104 0.026 DBMET00328 0.126 0.015 DBMET01513 0.09 0.038 DBMET00137 | DBMET01513 | |
| 0.087 | 0.044 | 0.102 | CC chemokine 5 receptor agonist | 0.088 0.04 DBMET00328 0.096 0.026 DBMET01513 0.102 0.019 DBMET00137 | DBMET00137 | |
| 0.052 | 0.01 | 0.084 | Glutamate (mGluR8) agonist | 0.058 0.008 DBMET00328 0.084 0.004 DBMET01513 0.073 0.005 DBMET00137 | DBMET01513 | |
| 0.082 | 0.041 | 0.095 | MAP kinase kinase 7 inhibitor | 0.081 0.043 DBMET00328 0.09 0.024 DBMET01513 0.095 0.017 DBMET00137 | DBMET00137 | |
| 0.07 | 0.03 | 0.075 | Transcription factor RelA inhibitor | 0.065 0.039 DBMET00328 0.072 0.026 DBMET01513 0.075 0.022 DBMET00137 | DBMET00137 | |
| 0.072 | 0.032 | 0.104 | Interferon inducer | 0.064 0.045 DBMET00328 0.104 0.011 DBMET01513 0.075 0.029 DBMET00137 | DBMET01513 | |
| 0.052 | 0.012 | 0.086 | Kainate receptor agonist | 0.058 0.008 DBMET00328 0.086 0.003 DBMET01513 0.067 0.005 DBMET00137 | DBMET01513 | |
| 0.097 | 0.058 | 0.187 | HIV-1 integrase (Overall Integration) inhibitor | 0.103 0.052 DBMET00328 0.187 0.014 DBMET01513 0.158 0.023 DBMET00137 | DBMET01513 | |
| 0.083 | 0.045 | 0.203 | Keratolytic | 0.087 0.041 DBMET00328 0.203 0.008 DBMET01513 0.108 0.026 DBMET00137 | DBMET01513 | |
| 0.063 | 0.025 | 0.08 | Dihydroorotate oxidase inhibitor | 0.072 0.016 DBMET00328 0.078 0.012 DBMET01513 0.08 0.01 DBMET00137 | DBMET00137 | |
| 0.07 | 0.032 | 0.07 | Acetylcholine M3 receptor antagonist | |||
| 0.052 | 0.015 | 0.07 | Alpha 1d adrenoreceptor agonist | 0.061 0.01 DBMET00328 0.059 0.011 DBMET01513 0.07 0.007 DBMET00137 | DBMET00137 | |
| 0.04 | 0.004 | 0.045 | Vanilloid 2 agonist | 0.034 0.006 DBMET00328 0.045 0.003 DBMET01513 0.037 0.005 DBMET00137 | DBMET01513 | |
| 0.068 | 0.033 | 0.073 | Calcium channel P-type blocker | 0.063 0.045 DBMET00328 0.073 0.022 DBMET01513 0.073 0.022 DBMET00137 | DBMET00137 | |
| 0.054 | 0.019 | 0.073 | Geranyltranstransferase inhibitor | 0.073 0.006 DBMET00328 0.064 0.01 DBMET01513 0.061 0.013 DBMET00137 | DBMET00328 | |
| 0.054 | 0.02 | 0.058 | Cytokine production stimulant | 0.053 0.023 DBMET00328 0.058 0.014 DBMET01513 0.056 0.018 DBMET00137 | DBMET01513 | |
| 0.044 | 0.01 | 0.044 | Purinergic P2T antagonist | |||
| 0.063 | 0.03 | 0.087 | Ryanodine receptor antagonist | 0.062 0.032 DBMET00328 0.087 0.006 DBMET01513 0.075 0.012 DBMET00137 | DBMET01513 | |
| 0.093 | 0.06 | 0.359 | Alcohol dehydrogenase inhibitor | 0.359 0.004 DBMET00328 0.174 0.015 DBMET01513 0.108 0.044 DBMET00137 | DBMET00328 | |
| 0.039 | 0.007 | 0.047 | Purinergic P2Y15 antagonist | 0.041 0.007 DBMET00328 0.043 0.005 DBMET01513 0.047 0.004 DBMET00137 | DBMET00137 | |
| 0.042 | 0.011 | 0.056 | Uridine phosphorylase inhibitor | 0.034 0.015 DBMET00328 0.056 0.006 DBMET01513 0.049 0.008 DBMET00137 | DBMET01513 | |
| 0.036 | 0.005 | 0.036 | Imidazoline I1 receptor antagonist | 0.019 0.018 DBMET01513 0.022 0.013 DBMET00137 | ||
| 0.056 | 0.027 | 0.086 | Lysophosphatidic acid 3 receptor antagonist | 0.061 0.021 DBMET00328 0.086 0.007 DBMET01513 0.069 0.015 DBMET00137 | DBMET01513 | |
| 0.094 | 0.065 | 0.112 | Phosphodiesterase 6D inhibitor | 0.112 0.034 DBMET01513 0.099 0.055 DBMET00137 | DBMET01513 | |
| 0.051 | 0.021 | 0.07 | Histamine H2 receptor agonist | 0.055 0.018 DBMET00328 0.067 0.011 DBMET01513 0.07 0.01 DBMET00137 | DBMET00137 | |
| 0.055 | 0.026 | 0.063 | Potassium channel (Inward rectifier) activator | 0.052 0.031 DBMET00328 0.063 0.017 DBMET01513 0.061 0.019 DBMET00137 | DBMET01513 | |
| 0.126 | 0.098 | 0.167 | Diuretic | 0.167 0.063 DBMET01513 | DBMET01513 | |
| 0.031 | 0.004 | 0.036 | Lysophosphatidic acid receptor 3 agonist | 0.02 0.005 DBMET00328 0.036 0.003 DBMET01513 0.023 0.005 DBMET00137 | DBMET01513 | |
| 0.038 | 0.011 | 0.055 | Glutamate (mGluR3) agonist | 0.037 0.014 DBMET00328 0.055 0.004 DBMET01513 0.042 0.008 DBMET00137 | DBMET01513 | |
| 0.039 | 0.012 | 0.058 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.058 0.007 DBMET00328 0.048 0.009 DBMET01513 0.052 0.008 DBMET00137 | DBMET00328 | |
| 0.052 | 0.026 | 0.06 | Potassium channel (ATP-sensitive) activator | 0.05 0.03 DBMET00328 0.06 0.016 DBMET01513 0.058 0.018 DBMET00137 | DBMET01513 | |
| 0.058 | 0.032 | 0.077 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.068 0.023 DBMET00328 0.073 0.02 DBMET01513 0.077 0.018 DBMET00137 | DBMET00137 | |
| 0.121 | 0.095 | 0.144 | Nav1.6 sodium channel blocker | 0.114 0.105 DBMET00328 0.144 0.061 DBMET01513 0.142 0.063 DBMET00137 | DBMET01513 | |
| 0.047 | 0.023 | 0.065 | Glutamate (mGluR1a) antagonist | 0.065 0.013 DBMET01513 0.041 0.028 DBMET00137 | DBMET01513 | |
| 0.045 | 0.02 | 0.084 | Membrane dipeptidase inhibitor | 0.05 0.015 DBMET00328 0.084 0.005 DBMET01513 0.055 0.012 DBMET00137 | DBMET01513 | |
| 0.027 | 0.004 | 0.03 | Telomerase stimulant | 0.023 0.005 DBMET00328 0.03 0.003 DBMET01513 0.025 0.004 DBMET00137 | DBMET01513 | |
| 0.042 | 0.019 | 0.042 | Antibiotic Aminoglycoside-like | |||
| 0.074 | 0.051 | 0.087 | Potassium channel (Tandem pore domain) blocker | 0.08 0.035 DBMET00328 0.087 0.021 DBMET01513 0.084 0.026 DBMET00137 | DBMET01513 | |
| 0.056 | 0.034 | 0.069 | Immunoglobulin Fc receptor antagonist | 0.061 0.022 DBMET00328 0.069 0.012 DBMET01513 0.069 0.012 DBMET00137 | DBMET00137 | |
| 0.027 | 0.004 | 0.027 | Antibiotic Anthracycline-like | 0.019 0.012 DBMET00328 0.026 0.005 DBMET01513 0.023 0.007 DBMET00137 | ||
| 0.152 | 0.13 | 0.234 | Insulin sensitizer | 0.154 0.128 DBMET00328 0.234 0.044 DBMET01513 0.173 0.104 DBMET00137 | DBMET01513 | |
| 0.079 | 0.058 | 0.141 | Carbonic anhydrase VI inhibitor | 0.141 0.023 DBMET01513 0.095 0.042 DBMET00137 | DBMET01513 | |
| 0.029 | 0.007 | 0.029 | Corticosteroid-like | 0.021 0.016 DBMET01513 | ||
| 0.031 | 0.01 | 0.036 | Hedgehog signaling activator | 0.031 0.012 DBMET00328 0.034 0.008 DBMET01513 0.036 0.006 DBMET00137 | DBMET00137 | |
| 0.03 | 0.009 | 0.082 | Glutamate (mGluR1a) agonist | 0.041 0.005 DBMET00328 0.082 0.004 DBMET01513 0.05 0.005 DBMET00137 | DBMET01513 | |
| 0.091 | 0.071 | 0.117 | Bile acid receptor antagonist | 0.086 0.083 DBMET00328 0.117 0.022 DBMET01513 0.098 0.053 DBMET00137 | DBMET01513 | |
| 0.062 | 0.042 | 0.076 | Corticotropin releasing factor 2 receptor antagonist | 0.062 0.042 DBMET00328 0.074 0.023 DBMET01513 0.076 0.021 DBMET00137 | DBMET00137 | |
| 0.05 | 0.031 | 0.07 | Dopamine beta hydroxylase inhibitor | 0.055 0.021 DBMET00328 0.07 0.008 DBMET01513 0.063 0.012 DBMET00137 | DBMET01513 | |
| 0.025 | 0.005 | 0.051 | Carbonic anhydrase X inhibitor | 0.029 0.004 DBMET00328 0.051 0.003 DBMET01513 0.037 0.004 DBMET00137 | DBMET01513 | |
| 0.025 | 0.005 | 0.051 | Carbonic anhydrase VIII inhibitor | 0.029 0.004 DBMET00328 0.051 0.003 DBMET01513 0.037 0.004 DBMET00137 | DBMET01513 | |
| 0.03 | 0.011 | 0.031 | Thymidine phosphorylase inhibitor | 0.024 0.022 DBMET00328 0.027 0.015 DBMET01513 0.031 0.011 DBMET00137 | DBMET00137 | |
| 0.03 | 0.012 | 0.042 | Nicotinic acid receptor 2 antagonist | 0.032 0.01 DBMET00328 0.042 0.005 DBMET01513 0.037 0.006 DBMET00137 | DBMET01513 | |
| 0.043 | 0.025 | 0.055 | Thymidine kinase inhibitor | 0.039 0.031 DBMET00328 0.055 0.016 DBMET01513 0.05 0.019 DBMET00137 | DBMET01513 | |
| 0.045 | 0.027 | 0.058 | Histamine H1 receptor agonist | 0.049 0.02 DBMET00328 0.052 0.015 DBMET01513 0.058 0.01 DBMET00137 | DBMET00137 | |
| 0.094 | 0.077 | 0.2 | Falcipain 3 inhibitor | 0.2 0.018 DBMET00328 0.152 0.036 DBMET01513 0.148 0.038 DBMET00137 | DBMET00328 | |
| 0.084 | 0.067 | 0.102 | Bromodomain-containing protein 2 inhibitor | 0.09 0.055 DBMET00328 0.102 0.038 DBMET01513 0.102 0.038 DBMET00137 | DBMET00137 | |
| 0.029 | 0.012 | 0.046 | Lysophosphatidic acid receptor 1 agonist | 0.031 0.01 DBMET00328 0.046 0.004 DBMET01513 0.035 0.008 DBMET00137 | DBMET01513 | |
| 0.048 | 0.032 | 0.07 | Adenosine deaminase inhibitor | 0.07 0.014 DBMET00328 0.068 0.015 DBMET01513 0.06 0.021 DBMET00137 | DBMET00328 | |
| 0.039 | 0.024 | 0.046 | Potassium channel Kv1.1 blocker | 0.045 0.017 DBMET00328 0.046 0.016 DBMET01513 0.046 0.016 DBMET00137 | DBMET00137 | |
| 0.03 | 0.015 | 0.034 | Estrogen-related receptor gamma antagonist | 0.03 0.016 DBMET00328 0.034 0.01 DBMET01513 0.034 0.009 DBMET00137 | DBMET00137 | |
| 0.161 | 0.146 | 0.29 | Immunostimulant | 0.25 0.096 DBMET00328 0.29 0.081 DBMET01513 0.173 0.137 DBMET00137 | DBMET01513 | |
| 0.036 | 0.021 | 0.038 | Adenosine uptake inhibitor | 0.038 0.015 DBMET01513 0.037 0.017 DBMET00137 | DBMET01513 | |
| 0.058 | 0.044 | 0.094 | Androgen agonist | 0.057 0.045 DBMET00328 0.094 0.017 DBMET01513 0.067 0.034 DBMET00137 | DBMET01513 | |
| 0.04 | 0.026 | 0.068 | GABA uptake inhibitor | 0.068 0.008 DBMET00328 0.067 0.008 DBMET01513 0.057 0.011 DBMET00137 | DBMET00328 | |
| 0.039 | 0.025 | 0.06 | Vanilloid 3 antagonist | 0.038 0.026 DBMET00328 0.06 0.005 DBMET01513 0.046 0.012 DBMET00137 | DBMET01513 | |
| 0.026 | 0.012 | 0.04 | Prostaglandin F2 alpha agonist | 0.023 0.014 DBMET00328 0.04 0.005 DBMET01513 0.027 0.011 DBMET00137 | DBMET01513 | |
| 0.027 | 0.013 | 0.033 | Complement factor 1s inhibitor | 0.029 0.01 DBMET00328 0.03 0.008 DBMET01513 0.033 0.005 DBMET00137 | DBMET00137 | |
| 0.043 | 0.029 | 0.06 | Nerve growth factor antagonist | 0.048 0.02 DBMET00328 0.056 0.012 DBMET01513 0.06 0.01 DBMET00137 | DBMET00137 | |
| 0.061 | 0.048 | 0.079 | 5 Hydroxytryptamine 3 agonist | 0.059 0.05 DBMET00328 0.063 0.044 DBMET01513 0.079 0.028 DBMET00137 | DBMET00137 | |
| 0.052 | 0.039 | 0.067 | Nicotinic alpha3beta2 receptor antagonist | 0.052 0.04 DBMET00328 0.067 0.02 DBMET01513 0.063 0.023 DBMET00137 | DBMET01513 | |
| 0.031 | 0.019 | 0.042 | Nicotinic alpha3beta4 receptor agonist | 0.03 0.021 DBMET00328 0.035 0.014 DBMET01513 0.042 0.009 DBMET00137 | DBMET00137 | |
| 0.078 | 0.066 | 0.176 | Calcium antagonist | 0.084 0.06 DBMET00328 0.176 0.017 DBMET01513 0.101 0.047 DBMET00137 | DBMET01513 | |
| 0.037 | 0.025 | 0.073 | Arginase inhibitor | 0.037 0.025 DBMET00328 0.073 0.007 DBMET01513 0.051 0.014 DBMET00137 | DBMET01513 | |
| 0.096 | 0.084 | 0.106 | Protein kinase C gamma inhibitor | 0.106 0.068 DBMET01513 0.102 0.074 DBMET00137 | DBMET01513 | |
| 0.042 | 0.031 | 0.05 | Heme oxygenase inhibitor | 0.041 0.037 DBMET00328 0.046 0.02 DBMET01513 0.05 0.013 DBMET00137 | DBMET00137 | |
| 0.02 | 0.009 | 0.027 | Methylmalonyl-CoA mutase inhibitor | 0.027 0.003 DBMET00328 0.026 0.004 DBMET01513 0.023 0.005 DBMET00137 | DBMET00328 | |
| 0.019 | 0.007 | 0.019 | Purinergic P2Y1 agonist | 0.016 0.01 DBMET00328 0.018 0.008 DBMET01513 0.019 0.007 DBMET00137 | ||
| 0.027 | 0.016 | 0.031 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.026 0.02 DBMET00328 0.029 0.013 DBMET01513 0.031 0.01 DBMET00137 | DBMET00137 | |
| 0.077 | 0.066 | 0.128 | Glutathione S-transferase inhibitor | 0.087 0.052 DBMET00328 0.128 0.019 DBMET01513 0.088 0.05 DBMET00137 | DBMET01513 | |
| 0.015 | 0.005 | 0.015 | Imidazoline I2 receptor antagonist | |||
| 0.052 | 0.041 | 0.064 | Heparanase inhibitor | 0.054 0.034 DBMET00328 0.064 0.017 DBMET01513 0.055 0.033 DBMET00137 | DBMET01513 | |
| 0.032 | 0.021 | 0.041 | Potassium channel small-conductance Ca-activated activator | 0.028 0.026 DBMET00328 0.033 0.02 DBMET01513 0.041 0.015 DBMET00137 | DBMET00137 | |
| 0.066 | 0.055 | 0.075 | Protein kinase C beta inhibitor | 0.063 0.062 DBMET00328 0.075 0.039 DBMET01513 0.071 0.046 DBMET00137 | DBMET01513 | |
| 0.063 | 0.054 | 0.063 | Potassium channel (ATP-sensitive) blocker | 0.062 0.056 DBMET01513 | ||
| 0.092 | 0.083 | 0.114 | Beta glucuronidase inhibitor | 0.11 0.056 DBMET00328 0.114 0.051 DBMET01513 0.099 0.071 DBMET00137 | DBMET01513 | |
| 0.04 | 0.032 | 0.058 | Oxytocin agonist | 0.051 0.023 DBMET00328 0.056 0.02 DBMET01513 0.058 0.019 DBMET00137 | DBMET00137 | |
| 0.165 | 0.157 | 0.279 | Calpain inhibitor | 0.279 0.042 DBMET00328 0.234 0.081 DBMET01513 0.188 0.125 DBMET00137 | DBMET00328 | |
| 0.021 | 0.013 | 0.031 | Retinoid X beta receptor antagonist | 0.023 0.009 DBMET00328 0.031 0.004 DBMET01513 0.024 0.008 DBMET00137 | DBMET01513 | |
| 0.026 | 0.018 | 0.026 | Sodium/glucose cotransporter 2 inhibitor | 0.026 0.019 DBMET01513 0.025 0.021 DBMET00137 | ||
| 0.036 | 0.029 | 0.057 | Retinoid X receptor antagonist | 0.04 0.024 DBMET00328 0.057 0.008 DBMET01513 0.043 0.019 DBMET00137 | DBMET01513 | |
| 0.038 | 0.031 | 0.065 | Toll-Like receptor 2 agonist | 0.036 0.034 DBMET00328 0.065 0.019 DBMET01513 0.044 0.027 DBMET00137 | DBMET01513 | |
| 0.056 | 0.05 | 0.128 | NMDA receptor glycine site agonist | 0.069 0.037 DBMET00328 0.128 0.007 DBMET01513 0.092 0.021 DBMET00137 | DBMET01513 | |
| 0.028 | 0.021 | 0.037 | Nicotinic alpha4beta2 receptor agonist | 0.032 0.015 DBMET00328 0.031 0.016 DBMET01513 0.037 0.01 DBMET00137 | DBMET00137 | |
| 0.033 | 0.026 | 0.05 | Retinoid X alpha receptor antagonist | 0.036 0.021 DBMET00328 0.05 0.007 DBMET01513 0.039 0.017 DBMET00137 | DBMET01513 | |
| 0.054 | 0.048 | 0.097 | Carbonic anhydrase stimulant | 0.058 0.043 DBMET00328 0.097 0.019 DBMET01513 0.075 0.029 DBMET00137 | DBMET01513 | |
| 0.056 | 0.05 | 0.086 | Potassium channel intermediate-conductance Ca-activated blocker | 0.067 0.03 DBMET00328 0.086 0.014 DBMET01513 0.075 0.022 DBMET00137 | DBMET01513 | |
| 0.022 | 0.016 | 0.03 | Isoleucine-tRNA ligase inhibitor | 0.023 0.015 DBMET00328 0.03 0.005 DBMET01513 0.026 0.01 DBMET00137 | DBMET01513 | |
| 0.051 | 0.045 | 0.06 | Thromboxane synthase inhibitor | 0.06 0.028 DBMET01513 | DBMET01513 | |
| 0.044 | 0.039 | 0.065 | Aldosterone antagonist | 0.065 0.017 DBMET01513 0.056 0.023 DBMET00137 | DBMET01513 | |
| 0.024 | 0.019 | 0.029 | Prostaglandin H2 antagonist | 0.029 0.014 DBMET01513 | DBMET01513 | |
| 0.076 | 0.071 | 0.102 | Caspase 7 inhibitor | 0.102 0.026 DBMET00328 0.1 0.028 DBMET01513 0.087 0.047 DBMET00137 | DBMET00328 | |
| 0.013 | 0.009 | 0.02 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.015 0.007 DBMET00328 0.019 0.004 DBMET01513 0.02 0.004 DBMET00137 | DBMET00137 | |
| 0.059 | 0.055 | 0.124 | Sphingosine 1-phosphate receptor 4 agonist | 0.075 0.04 DBMET00328 0.124 0.015 DBMET01513 0.088 0.031 DBMET00137 | DBMET01513 | |
| 0.026 | 0.022 | 0.035 | Glucosylceramidase stimulant | 0.029 0.013 DBMET00328 0.035 0.006 DBMET01513 0.031 0.011 DBMET00137 | DBMET01513 | |
| 0.047 | 0.043 | 0.173 | Protein 50S ribosomal subunit inhibitor | 0.173 0.005 DBMET00328 0.054 0.036 DBMET01513 | DBMET00328 | |
| 0.049 | 0.046 | 0.102 | Carbonic anhydrase VB inhibitor | 0.102 0.016 DBMET01513 0.073 0.026 DBMET00137 | DBMET01513 | |
| 0.024 | 0.021 | 0.031 | Acid ceramidase inhibitor | 0.026 0.017 DBMET00328 0.03 0.01 DBMET01513 0.031 0.008 DBMET00137 | DBMET00137 | |
| 0.103 | 0.1 | 0.14 | Transcription factor STAT6 inhibitor | 0.103 0.097 DBMET00328 0.14 0.032 DBMET01513 0.124 0.054 DBMET00137 | DBMET01513 | |
| 0.065 | 0.063 | 0.151 | Carbonic anhydrase XIII inhibitor | 0.119 0.03 DBMET00328 0.151 0.021 DBMET01513 0.084 0.047 DBMET00137 | DBMET01513 | |
| 0.024 | 0.022 | 0.025 | Sodium/glucose cotransporter inhibitor | 0.025 0.02 DBMET01513 0.024 0.023 DBMET00137 | DBMET01513 | |
| 0.05 | 0.048 | 0.067 | Sphingosine kinase 2 inhibitor | 0.052 0.044 DBMET00328 0.058 0.034 DBMET01513 0.067 0.024 DBMET00137 | DBMET00137 | |
| 0.01 | 0.008 | 0.01 | Purinergic P2Y2 agonist | 0.01 0.008 DBMET00137 | ||
| 0.12 | 0.118 | 0.184 | Phospholipase A2 inhibitor | 0.139 0.087 DBMET00328 0.184 0.051 DBMET01513 | DBMET01513 | |
| 0.011 | 0.009 | 0.024 | Glutamate (mGluR6) agonist | 0.012 0.008 DBMET00328 0.024 0.004 DBMET01513 0.019 0.004 DBMET00137 | DBMET01513 | |
| 0.02 | 0.018 | 0.029 | Neuraminidase (Influenza B) inhibitor | 0.022 0.011 DBMET00328 0.029 0.005 DBMET01513 0.025 0.008 DBMET00137 | DBMET01513 | |
| 0.033 | 0.031 | 0.064 | Glutamate (mGluR3) antagonist | 0.064 0.007 DBMET01513 0.048 0.014 DBMET00137 | DBMET01513 | |
| 0.031 | 0.029 | 0.051 | Free fatty acid receptor 1 antagonist | 0.051 0.009 DBMET01513 0.036 0.02 DBMET00137 | DBMET01513 | |
| 0.025 | 0.024 | 0.025 | Myristoyl transferase inhibitor | |||
| 0.019 | 0.018 | 0.025 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.02 0.015 DBMET00328 0.024 0.008 DBMET01513 0.025 0.007 DBMET00137 | DBMET00137 | |
| 0.03 | 0.03 | 0.087 | Retinoid X alpha receptor agonist | 0.032 0.027 DBMET00328 0.087 0.006 DBMET01513 0.04 0.019 DBMET00137 | DBMET01513 | |
| 0.044 | 0.044 | 0.059 | HCV NS3/NS4A protease inhibitor | 0.059 0.022 DBMET00328 0.058 0.023 DBMET01513 0.049 0.033 DBMET00137 | DBMET00328 | |
| 0.011 | 0.011 | 0.022 | Carbonic anhydrase XI inhibitor | 0.013 0.009 DBMET00328 0.022 0.004 DBMET01513 0.018 0.005 DBMET00137 | DBMET01513 | |
| 0.007 | 0.006 | 0.009 | DNA topoisomerase III inhibitor | 0.007 0.005 DBMET00328 0.008 0.005 DBMET01513 0.009 0.004 DBMET00137 | DBMET00137 | |
| 0.014 | 0.014 | 0.025 | Thromboxane A2 agonist | 0.018 0.007 DBMET00328 0.025 0.004 DBMET01513 0.021 0.005 DBMET00137 | DBMET01513 | |
| 0.03 | 0.031 | 0.047 | Phosphoglycerate kinase inhibitor | 0.036 0.023 DBMET00328 0.047 0.015 DBMET01513 0.042 0.018 DBMET00137 | DBMET01513 | |
| 0.065 | 0.067 | 0.143 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.079 0.052 DBMET00328 0.143 0.021 DBMET01513 0.089 0.044 DBMET00137 | DBMET01513 | |
| 0.022 | 0.024 | 0.045 | Glutamate (mGluR1) agonist | 0.028 0.012 DBMET00328 0.045 0.005 DBMET01513 0.03 0.01 DBMET00137 | DBMET01513 | |
| 0.033 | 0.034 | 0.047 | Tryptophan 5 hydroxylase inhibitor | 0.034 0.032 DBMET00328 0.047 0.007 DBMET01513 0.041 0.013 DBMET00137 | DBMET01513 | |
| 0.03 | 0.032 | 0.04 | Melatonin receptor 1A agonist | 0.035 0.021 DBMET00328 0.04 0.013 DBMET01513 0.037 0.018 DBMET00137 | DBMET01513 | |
| 0.008 | 0.01 | 0.011 | Progesterone receptor A antagonist | 0.011 0.005 DBMET01513 | DBMET01513 | |
| 0.063 | 0.065 | 0.088 | MDM2 inhibitor | 0.066 0.051 DBMET00328 0.088 0.012 DBMET01513 0.076 0.026 DBMET00137 | DBMET01513 | |
| 0.046 | 0.048 | 0.049 | Carbonic anhydrase II inhibitor | 0.049 0.045 DBMET01513 | DBMET01513 | |
| 0.057 | 0.06 | 0.065 | Aryl hydrocarbon receptor antagonist | 0.065 0.044 DBMET00137 | DBMET00137 | |
| 0.012 | 0.015 | 0.014 | Cyclin D2 inhibitor | 0.014 0.009 DBMET01513 0.014 0.007 DBMET00137 | DBMET00137 | |
| 0.031 | 0.035 | 0.038 | Ceramide glucosyltransferase inhibitor | 0.034 0.027 DBMET01513 0.038 0.021 DBMET00137 | DBMET00137 | |
| 0.033 | 0.037 | 0.041 | Delayed rectifier potassium channel blocker | 0.038 0.024 DBMET01513 0.041 0.019 DBMET00137 | DBMET00137 | |
| 0.054 | 0.058 | 0.144 | NMDA receptor agonist | 0.062 0.044 DBMET00328 0.144 0.009 DBMET01513 0.087 0.025 DBMET00137 | DBMET01513 | |
| 0.05 | 0.054 | 0.054 | 5 Hydroxytryptamine 7 agonist | 0.054 0.043 DBMET00137 | DBMET00137 | |
| 0.014 | 0.018 | 0.018 | Alpha 2a adrenoreceptor agonist | 0.018 0.011 DBMET00137 | DBMET00137 | |
| 0.033 | 0.038 | 0.061 | Dihydropteroate synthase inhibitor | 0.061 0.011 DBMET01513 0.049 0.018 DBMET00137 | DBMET01513 | |
| 0.018 | 0.024 | 0.023 | Factor XIII inhibitor | 0.021 0.015 DBMET01513 0.023 0.01 DBMET00137 | DBMET00137 | |
| 0.024 | 0.03 | 0.034 | Peptide deformylase inhibitor | 0.027 0.025 DBMET00328 0.034 0.018 DBMET01513 0.03 0.021 DBMET00137 | DBMET01513 | |
| 0.004 | 0.011 | 0.006 | CC chemokine 6 receptor agonist | 0.006 0.004 DBMET00137 | DBMET00137 | |
| 0.026 | 0.032 | 0.042 | Epoxide hydrolase 1 inhibitor | 0.03 0.023 DBMET00328 0.042 0.009 DBMET01513 0.037 0.014 DBMET00137 | DBMET01513 | |
| 0.016 | 0.023 | 0.02 | Alpha 2b adrenoreceptor agonist | 0.02 0.01 DBMET00328 0.018 0.016 DBMET00137 | DBMET00328 | |
| 0.018 | 0.026 | 0.03 | Protease (Human cytomegalovirus) inhibitor | 0.03 0.008 DBMET01513 0.025 0.011 DBMET00137 | DBMET01513 | |
| 0.021 | 0.029 | 0.04 | Lysine carboxypeptidase inhibitor | 0.04 0.01 DBMET01513 0.033 0.013 DBMET00137 | DBMET01513 | |
| 0.013 | 0.022 | 0.017 | Vitamin D receptor agonist | 0.017 0.01 DBMET01513 | DBMET01513 | |
| 0.051 | 0.06 | 0.066 | Leukotriene C antagonist | 0.066 0.019 DBMET01513 0.058 0.035 DBMET00137 | DBMET01513 | |
| 0.013 | 0.022 | 0.023 | Nicotinic acid receptor 1 antagonist | 0.023 0.007 DBMET01513 0.022 0.007 DBMET00137 | DBMET01513 | |
| 0.026 | 0.035 | 0.076 | Retinoid X receptor agonist | 0.031 0.028 DBMET00328 0.076 0.008 DBMET01513 0.038 0.024 DBMET00137 | DBMET01513 | |
| 0.048 | 0.057 | 0.071 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.071 0.03 DBMET01513 0.054 0.047 DBMET00137 | DBMET01513 | |
| 0.026 | 0.035 | 0.043 | ATP citrate lysase inhibitor | 0.043 0.011 DBMET01513 0.033 0.021 DBMET00137 | DBMET01513 | |
| 0.024 | 0.034 | 0.048 | Lysophosphatidic acid 2 receptor antagonist | 0.048 0.009 DBMET01513 0.032 0.019 DBMET00137 | DBMET01513 | |
| 0.037 | 0.047 | 0.066 | AICAR transformylase inhibitor | 0.066 0.011 DBMET00328 0.061 0.014 DBMET01513 0.054 0.018 DBMET00137 | DBMET00328 | |
| 0.034 | 0.044 | 0.05 | Purinergic P2Y antagonist | 0.05 0.026 DBMET01513 | DBMET01513 | |
| 0.063 | 0.073 | 0.105 | Nicotinic alpha4beta2 receptor antagonist | 0.097 0.034 DBMET00328 0.105 0.027 DBMET01513 0.089 0.041 DBMET00137 | DBMET01513 | |
| 0.048 | 0.059 | 0.056 | Carbonic anhydrase inhibitor | 0.056 0.049 DBMET01513 | DBMET01513 | |
| 0.019 | 0.03 | 0.03 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.03 0.008 DBMET01513 0.023 0.017 DBMET00137 | DBMET01513 | |
| 0.036 | 0.048 | 0.063 | Fructose-1,6-bisphosphatase inhibitor | 0.063 0.016 DBMET01513 0.046 0.029 DBMET00137 | DBMET01513 | |
| 0.024 | 0.035 | 0.027 | 5 Hydroxytryptamine 6 agonist | 0.027 0.023 DBMET00137 | DBMET00137 | |
| 0.004 | 0.016 | 0.007 | Integrin alpha5beta6 antagonist | 0.007 0.004 DBMET01513 0.006 0.005 DBMET00137 | DBMET01513 | |
| 0.007 | 0.019 | 0.014 | Thromboxane agonist | 0.014 0.005 DBMET01513 0.01 0.008 DBMET00137 | DBMET01513 | |
| 0.036 | 0.048 | 0.06 | Dihydroorotase inhibitor | 0.042 0.036 DBMET00328 0.06 0.017 DBMET01513 0.049 0.026 DBMET00137 | DBMET01513 | |
| 0.012 | 0.024 | 0.02 | Cyclin T1 inhibitor | 0.02 0.011 DBMET00137 | DBMET00137 | |
| 0.012 | 0.024 | 0.018 | Nicotinic alpha4 receptor agonist | 0.018 0.009 DBMET00328 0.016 0.013 DBMET01513 0.016 0.011 DBMET00137 | DBMET00328 | |
| 0.041 | 0.054 | 0.063 | Prolyl endopeptidase inhibitor | 0.057 0.027 DBMET00328 0.063 0.021 DBMET01513 0.053 0.032 DBMET00137 | DBMET01513 | |
| 0.08 | 0.093 | 0.146 | Interleukin 1 beta converting enzyme inhibitor | 0.146 0.019 DBMET00328 0.136 0.024 DBMET01513 0.089 0.073 DBMET00137 | DBMET00328 | |
| 0.024 | 0.037 | 0.039 | Calcitonin receptor agonist | 0.031 0.026 DBMET00328 0.039 0.02 DBMET01513 0.033 0.024 DBMET00137 | DBMET01513 | |
| 0.046 | 0.06 | 0.07 | Glucosylceramidase inhibitor | 0.07 0.022 DBMET00328 0.052 0.044 DBMET01513 0.056 0.036 DBMET00137 | DBMET00328 | |
| 0.032 | 0.047 | 0.038 | 5 Hydroxytryptamine 2B agonist | 0.038 0.028 DBMET00137 | DBMET00137 | |
| 0.013 | 0.028 | 0.017 | CC chemokine 9 receptor antagonist | 0.017 0.012 DBMET01513 0.016 0.015 DBMET00137 | DBMET01513 | |
| 0.085 | 0.1 | 0.184 | Adenylate cyclase inhibitor | 0.184 0.029 DBMET01513 0.122 0.066 DBMET00137 | DBMET01513 | |
| 0.036 | 0.051 | 0.068 | Microtubule stabilization | 0.068 0.007 DBMET01513 | DBMET01513 | |
| 0.014 | 0.03 | 0.024 | Estrogen-related receptor gamma agonist | 0.024 0.006 DBMET01513 0.017 0.016 DBMET00137 | DBMET01513 | |
| 0.027 | 0.043 | 0.037 | Carboxypeptidase B inhibitor | 0.037 0.016 DBMET01513 0.031 0.027 DBMET00137 | DBMET01513 | |
| 0.006 | 0.022 | 0.01 | Angiotensin AT2 receptor agonist | 0.01 0.008 DBMET01513 | DBMET01513 | |
| 0.038 | 0.055 | 0.058 | Cholesterol esterase inhibitor | 0.058 0.019 DBMET01513 0.046 0.036 DBMET00137 | DBMET01513 | |
| 0.026 | 0.042 | 0.054 | 5-Alpha-reductase inhibitor | 0.054 0.017 DBMET01513 | DBMET01513 | |
| 0.054 | 0.071 | 0.108 | Carbonic anhydrase VA inhibitor | 0.108 0.022 DBMET01513 0.076 0.04 DBMET00137 | DBMET01513 | |
| 0.015 | 0.032 | 0.021 | Caspase 8 inhibitor | 0.021 0.011 DBMET00328 0.021 0.011 DBMET01513 | DBMET01513 | |
| 0.01 | 0.028 | 0.019 | Aminopeptidase A inhibitor | 0.019 0.011 DBMET01513 | DBMET01513 | |
| 0.036 | 0.053 | 0.075 | Glutamate (mGluR4) antagonist | 0.042 0.034 DBMET00328 0.075 0.009 DBMET01513 0.053 0.018 DBMET00137 | DBMET01513 | |
| 0.035 | 0.053 | 0.052 | GABA B receptor antagonist | 0.052 0.017 DBMET01513 0.042 0.032 DBMET00137 | DBMET01513 | |
| 0.02 | 0.038 | 0.031 | Thyroid hormone agonist | 0.031 0.011 DBMET01513 | DBMET01513 | |
| 0.012 | 0.031 | 0.017 | Alpha 2c adrenoreceptor agonist | 0.017 0.015 DBMET00328 | DBMET00328 | |
| 0.019 | 0.039 | 0.039 | Acetylcholine M4 receptor agonist | 0.039 0.015 DBMET01513 0.03 0.022 DBMET00137 | DBMET01513 | |
| 0.048 | 0.069 | 0.068 | Sphingosine kinase inhibitor | 0.067 0.028 DBMET00328 0.068 0.027 DBMET01513 0.06 0.038 DBMET00137 | DBMET01513 | |
| 0.078 | 0.099 | 0.121 | Xanthine oxidase inhibitor | 0.086 0.079 DBMET00328 0.121 0.047 DBMET01513 0.084 0.083 DBMET00137 | DBMET01513 | |
| 0.013 | 0.034 | 0.019 | CXC chemokine 5 receptor antagonist | 0.019 0.01 DBMET01513 | DBMET01513 | |
| 0.036 | 0.057 | 0.069 | Glutamate (mGluR group III) antagonist | 0.041 0.038 DBMET00328 0.069 0.01 DBMET01513 0.05 0.021 DBMET00137 | DBMET01513 | |
| 0.004 | 0.025 | 0.021 | Antibiotic Macrolide-like | 0.021 0.006 DBMET00328 | DBMET00328 | |
| 0.032 | 0.054 | 0.062 | Antimetabolite | 0.046 0.034 DBMET00328 0.062 0.025 DBMET01513 | DBMET01513 | |
| 0.008 | 0.029 | 0.016 | Human herpes virus 5 capsid protein P40 inhibitor | 0.016 0.005 DBMET01513 | DBMET01513 | |
| 0.033 | 0.055 | 0.043 | Leukotriene C4 antagonist | 0.043 0.018 DBMET01513 0.037 0.032 DBMET00137 | DBMET01513 | |
| 0.02 | 0.042 | 0.03 | Integrin alpha2beta1 antagonist | 0.03 0.012 DBMET01513 0.028 0.015 DBMET00137 | DBMET01513 | |
| 0.009 | 0.031 | 0.02 | Ileal bile acid transport inhibitor | 0.02 0.009 DBMET01513 | DBMET01513 | |
| 0.023 | 0.045 | 0.031 | MAP3K8 inhibitor | 0.028 0.024 DBMET01513 0.031 0.017 DBMET00137 | DBMET00137 | |
| 0.097 | 0.122 | 0.121 | Alkaline phosphatase inhibitor | 0.121 0.085 DBMET01513 | DBMET01513 | |
| 0.053 | 0.078 | 0.065 | Histone deacetylase SIRT3 inhibitor | 0.058 0.056 DBMET00328 0.063 0.041 DBMET01513 0.065 0.037 DBMET00137 | DBMET00137 | |
| 0.086 | 0.111 | 0.142 | Beta amyloid protein antagonist | 0.142 0.046 DBMET01513 | DBMET01513 | |
| 0.039 | 0.064 | 0.054 | Bombesin 2 receptor antagonist | 0.054 0.028 DBMET01513 0.049 0.034 DBMET00137 | DBMET01513 | |
| 0.081 | 0.107 | 0.183 | Anesthetic local | 0.129 0.061 DBMET00328 0.183 0.037 DBMET01513 0.094 0.088 DBMET00137 | DBMET01513 | |
| 0.034 | 0.06 | 0.041 | CF transmembrane conductance regulator antagonist | 0.038 0.035 DBMET01513 0.041 0.024 DBMET00137 | DBMET00137 | |
| 0.016 | 0.041 | 0.036 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.036 0.013 DBMET01513 | DBMET01513 | |
| 0.181 | 0.207 | 0.406 | Calpain 2 inhibitor | 0.406 0.058 DBMET00328 0.286 0.123 DBMET01513 0.21 0.179 DBMET00137 | DBMET00328 | |
| 0.025 | 0.051 | 0.04 | Diamine oxidase inhibitor | 0.037 0.027 DBMET01513 0.04 0.023 DBMET00137 | DBMET00137 | |
| 0.046 | 0.073 | 0.081 | Acetyl-CoA transferase 2 inhibitor | 0.081 0.01 DBMET01513 | DBMET01513 | |
| 0.031 | 0.058 | 0.042 | Sphingosine kinase 1 inhibitor | 0.042 0.027 DBMET01513 0.039 0.032 DBMET00137 | DBMET01513 | |
| 0.021 | 0.049 | 0.034 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.034 0.02 DBMET01513 | DBMET01513 | |
| 0.047 | 0.075 | 0.112 | Carbonic anhydrase V inhibitor | 0.112 0.023 DBMET01513 0.07 0.042 DBMET00137 | DBMET01513 | |
| 0.035 | 0.063 | 0.048 | CC chemokine 4 receptor antagonist | 0.046 0.035 DBMET01513 0.048 0.031 DBMET00137 | DBMET00137 | |
| 0.006 | 0.035 | 0.011 | Egl nine homolog 3 inhibitor | 0.011 0.01 DBMET01513 | DBMET01513 | |
| 0.012 | 0.04 | 0.02 | 5-Alpha-reductase 2 inhibitor | 0.02 0.013 DBMET01513 | DBMET01513 | |
| 0.119 | 0.148 | 0.31 | Psychostimulant | 0.169 0.101 DBMET00328 0.31 0.04 DBMET01513 0.149 0.117 DBMET00137 | DBMET01513 | |
| 0.027 | 0.056 | 0.042 | Integrin alpha2 antagonist | 0.042 0.018 DBMET01513 0.038 0.023 DBMET00137 | DBMET01513 | |
| 0.098 | 0.128 | 0.16 | Antibacterial (Helicobacter pylori) | 0.16 0.039 DBMET01513 | DBMET01513 | |
| 0.067 | 0.097 | 0.076 | Histamine H2 receptor antagonist | 0.076 0.074 DBMET00137 | DBMET00137 | |
| 0.044 | 0.074 | 0.076 | Cyclin D1 inhibitor | 0.076 0.022 DBMET00328 0.057 0.048 DBMET01513 0.064 0.036 DBMET00137 | DBMET00328 | |
| 0.029 | 0.06 | 0.053 | Angiotensin AT1 receptor antagonist | 0.053 0.013 DBMET01513 0.04 0.033 DBMET00137 | DBMET01513 | |
| 0.033 | 0.064 | 0.044 | Glutamate (mGluR5) agonist | 0.044 0.035 DBMET01513 0.044 0.034 DBMET00137 | DBMET00137 | |
| 0.164 | 0.196 | 0.22 | Neuropeptide Y2 antagonist | 0.193 0.133 DBMET00328 0.22 0.088 DBMET01513 0.21 0.103 DBMET00137 | DBMET01513 | |
| 0.021 | 0.053 | 0.046 | Methionyl aminopeptidase 1 inhibitor | 0.046 0.008 DBMET01513 0.033 0.021 DBMET00137 | DBMET01513 | |
| 0.011 | 0.043 | 0.02 | Complement factor D inhibitor | 0.02 0.01 DBMET01513 0.018 0.012 DBMET00137 | DBMET01513 | |
| 0.014 | 0.046 | 0.022 | Lysophosphatidic acid 1 receptor antagonist | 0.022 0.014 DBMET01513 | DBMET01513 | |
| 0.058 | 0.09 | 0.089 | Acetylcholine nicotinic antagonist | 0.089 0.047 DBMET01513 | DBMET01513 | |
| 0.055 | 0.088 | 0.065 | Secretase beta inhibitor | 0.064 0.062 DBMET01513 0.065 0.058 DBMET00137 | DBMET00137 | |
| 0.006 | 0.039 | 0.016 | G-protein-coupled receptor 120 agonist | 0.016 0.013 DBMET01513 | DBMET01513 | |
| 0.02 | 0.054 | 0.027 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.027 0.02 DBMET01513 | DBMET01513 | |
| 0.059 | 0.094 | 0.07 | Phosphodiesterase VI inhibitor | 0.07 0.063 DBMET01513 | DBMET01513 | |
| 0.039 | 0.074 | 0.053 | CD45 antagonist | 0.053 0.029 DBMET01513 0.047 0.042 DBMET00137 | DBMET01513 | |
| 0.025 | 0.061 | 0.037 | Protein kinase (CK2) beta inhibitor | 0.033 0.022 DBMET01513 0.037 0.016 DBMET00137 | DBMET00137 | |
| 0.066 | 0.102 | 0.146 | Monophenol monooxygenase inhibitor | 0.146 0.048 DBMET01513 | DBMET01513 | |
| 0.029 | 0.065 | 0.059 | Thymidylate synthase inhibitor | 0.051 0.026 DBMET00328 0.059 0.018 DBMET01513 0.047 0.031 DBMET00137 | DBMET01513 | |
| 0.032 | 0.068 | 0.047 | Dihydrofolate reductase inhibitor | 0.047 0.023 DBMET01513 | DBMET01513 | |
| 0.008 | 0.044 | 0.017 | 5-Alpha-reductase 1 inhibitor | 0.017 0.012 DBMET01513 | DBMET01513 | |
| 0.032 | 0.068 | 0.072 | Carbonic anhydrase XIV inhibitor | 0.072 0.019 DBMET01513 | DBMET01513 | |
| 0.116 | 0.153 | 0.173 | Tumour necrosis factor antagonist | 0.173 0.074 DBMET01513 | DBMET01513 | |
| 0.04 | 0.077 | 0.061 | Cyclin-dependent kinase 6 inhibitor | 0.055 0.047 DBMET01513 0.061 0.04 DBMET00137 | DBMET00137 | |
| 0.051 | 0.088 | 0.134 | Cathepsin G inhibitor | 0.122 0.027 DBMET00328 0.134 0.024 DBMET01513 0.072 0.051 DBMET00137 | DBMET01513 | |
| 0.041 | 0.079 | 0.073 | Sphingosine 1-phosphate receptor 3 antagonist | 0.073 0.022 DBMET01513 0.058 0.042 DBMET00137 | DBMET01513 | |
| 0.016 | 0.054 | 0.028 | Endothelial nitric-oxide synthase inhibitor | 0.028 0.025 DBMET01513 | DBMET01513 | |
| 0.089 | 0.127 | 0.143 | Interleukin 8 antagonist | 0.143 0.039 DBMET01513 0.107 0.081 DBMET00137 | DBMET01513 | |
| 0.115 | 0.153 | 0.136 | MAP kinase 3 inhibitor | 0.128 0.112 DBMET01513 0.136 0.092 DBMET00137 | DBMET00137 | |
| 0.048 | 0.086 | 0.06 | Phosphodiesterase 1A inhibitor | 0.06 0.042 DBMET01513 0.059 0.044 DBMET00137 | DBMET01513 | |
| 0.009 | 0.049 | 0.029 | Prostaglandin EP2 agonist | 0.029 0.013 DBMET01513 | DBMET01513 | |
| 0.023 | 0.062 | 0.041 | Angiotensin II receptor antagonist | 0.041 0.013 DBMET01513 | DBMET01513 | |
| 0.022 | 0.062 | 0.03 | Dipeptidyl peptidase II inhibitor | 0.03 0.027 DBMET01513 0.03 0.026 DBMET00137 | DBMET00137 | |
| 0.07 | 0.111 | 0.109 | Gastric antisecretory | 0.109 0.054 DBMET01513 | DBMET01513 | |
| 0.018 | 0.061 | 0.053 | Nicotinic acid receptor agonist | 0.053 0.014 DBMET01513 0.032 0.031 DBMET00137 | DBMET01513 | |
| 0.023 | 0.066 | 0.037 | Vascular adhesion protein 1 inhibitor | 0.037 0.03 DBMET00137 | DBMET00137 | |
| 0.016 | 0.059 | 0.035 | Prostaglandin agonist | 0.035 0.017 DBMET01513 | DBMET01513 | |
| 0.004 | 0.048 | 0.014 | Angiotensin AT1B receptor antagonist | 0.014 0.009 DBMET01513 | DBMET01513 | |
| 0.035 | 0.079 | 0.065 | Benzodiazepine antagonist | 0.065 0.009 DBMET01513 0.045 0.039 DBMET00137 | DBMET01513 | |
| 0.026 | 0.07 | 0.042 | MAP3K5 inhibitor | 0.042 0.022 DBMET01513 0.037 0.03 DBMET00137 | DBMET01513 | |
| 0.028 | 0.072 | 0.084 | Potassium channel Kv1.3 blocker | 0.042 0.039 DBMET00328 0.084 0.011 DBMET01513 0.041 0.04 DBMET00137 | DBMET01513 | |
| 0.048 | 0.093 | 0.177 | Amidase inhibitor | 0.177 0.007 DBMET00328 0.067 0.053 DBMET01513 | DBMET00328 | |
| 0.033 | 0.078 | 0.047 | Purinergic P2X4 antagonist | 0.047 0.03 DBMET00137 | DBMET00137 | |
| 0.065 | 0.11 | 0.105 | Urease inhibitor | 0.087 0.081 DBMET00328 0.105 0.061 DBMET01513 0.102 0.064 DBMET00137 | DBMET01513 | |
| 0.027 | 0.073 | 0.054 | AMPA 4 receptor antagonist | 0.054 0.013 DBMET01513 0.039 0.028 DBMET00137 | DBMET01513 | |
| 0.023 | 0.07 | 0.036 | Glutamate (mGluR4) agonist | 0.036 0.021 DBMET01513 0.032 0.029 DBMET00137 | DBMET01513 | |
| 0.048 | 0.095 | 0.064 | Benzodiazepine agonist | 0.064 0.06 DBMET01513 | DBMET01513 | |
| 0.014 | 0.061 | 0.035 | Liver X receptor beta antagonist | 0.035 0.015 DBMET01513 | DBMET01513 | |
| 0.039 | 0.086 | 0.067 | Fatty acid synthase inhibitor | 0.067 0.028 DBMET01513 | DBMET01513 | |
| 0.018 | 0.065 | 0.033 | Cholesterol ester transfer protein antagonist | 0.033 0.019 DBMET01513 | DBMET01513 | |
| 0.117 | 0.165 | 0.247 | Aryl hydrocarbon receptor agonist | 0.145 0.14 DBMET00328 0.247 0.08 DBMET01513 0.161 0.127 DBMET00137 | DBMET01513 | |
| 0.015 | 0.063 | 0.023 | ICAM 1 antagonist | 0.023 0.015 DBMET01513 | DBMET01513 | |
| 0.06 | 0.108 | 0.115 | Inducible nitric-oxide synthase inhibitor | 0.115 0.027 DBMET01513 0.074 0.073 DBMET00137 | DBMET01513 | |
| 0.021 | 0.07 | 0.054 | Urate transporter 1 inhibitor | 0.054 0.017 DBMET01513 | DBMET01513 | |
| 0.048 | 0.097 | 0.059 | Phosphodiesterase 1C inhibitor | 0.059 0.051 DBMET01513 0.058 0.053 DBMET00137 | DBMET01513 | |
| 0.039 | 0.09 | 0.072 | Botulinum neurotoxin type A inhibitor | 0.072 0.023 DBMET01513 0.054 0.048 DBMET00137 | DBMET01513 | |
| 0.059 | 0.11 | 0.073 | Estrogen receptor alpha antagonist | 0.073 0.062 DBMET01513 | DBMET01513 | |
| 0.121 | 0.173 | 0.253 | Hypolipemic | 0.253 0.066 DBMET01513 | DBMET01513 | |
| 0.042 | 0.094 | 0.058 | Neuronal nicotinic receptor antagonist | 0.058 0.057 DBMET01513 | DBMET01513 | |
| 0.075 | 0.127 | 0.16 | Proteasome inhibitor | 0.16 0.041 DBMET00328 0.144 0.05 DBMET01513 0.1 0.088 DBMET00137 | DBMET00328 | |
| 0.027 | 0.079 | 0.04 | Nicotinic receptor alpha3 subunit antagonist | 0.04 0.036 DBMET00328 | DBMET00328 | |
| 0.025 | 0.077 | 0.062 | Ribonucleoside-diphosphate reductase inhibitor | 0.053 0.039 DBMET00328 0.062 0.033 DBMET01513 | DBMET01513 | |
| 0.054 | 0.107 | 0.116 | Macrophage migration inhibitory factor inhibitor | 0.116 0.027 DBMET01513 0.07 0.066 DBMET00137 | DBMET01513 | |
| 0.025 | 0.078 | 0.049 | Glutamate (mGluR group I) agonist | 0.049 0.031 DBMET00328 0.047 0.033 DBMET01513 0.042 0.04 DBMET00137 | DBMET00328 | |
| 0.024 | 0.078 | 0.063 | Ribonucleotide reductase inhibitor | 0.053 0.04 DBMET00328 0.063 0.034 DBMET01513 | DBMET01513 | |
| 0.054 | 0.108 | 0.1 | Androgen antagonist | 0.1 0.047 DBMET01513 | DBMET01513 | |
| 0.069 | 0.127 | 0.101 | MAP kinase kinase 1 inhibitor | 0.092 0.067 DBMET01513 0.101 0.055 DBMET00137 | DBMET00137 | |
| 0.048 | 0.107 | 0.06 | Beta 3 adrenoreceptor antagonist | 0.06 0.056 DBMET01513 0.06 0.056 DBMET00137 | DBMET00137 | |
| 0.017 | 0.077 | 0.042 | Farnesoid X receptor agonist | 0.042 0.021 DBMET01513 | DBMET01513 | |
| 0.009 | 0.07 | 0.024 | Methionyl aminopeptidase 2 inhibitor | 0.024 0.019 DBMET01513 | DBMET01513 | |
| 0.064 | 0.125 | 0.109 | Transcription factor NF kappa B stimulant | 0.109 0.031 DBMET01513 | DBMET01513 | |
| 0.015 | 0.075 | 0.025 | Calcium-sensing receptor agonist | 0.025 0.021 DBMET01513 | DBMET01513 | |
| 0.014 | 0.075 | 0.053 | Caspase 2 inhibitor | 0.053 0.011 DBMET00328 0.031 0.022 DBMET01513 | DBMET00328 | |
| 0.009 | 0.071 | 0.023 | NMDA receptor glycine site antagonist | 0.023 0.018 DBMET01513 | DBMET01513 | |
| 0.026 | 0.088 | 0.051 | Glutamate (mGluR group III) agonist | 0.051 0.023 DBMET01513 0.041 0.033 DBMET00137 | DBMET01513 | |
| 0.055 | 0.118 | 0.067 | Orexin receptor 1 antagonist | 0.067 0.066 DBMET00137 | DBMET00137 | |
| 0.058 | 0.121 | 0.086 | GABA A receptor agonist | 0.086 0.053 DBMET01513 | DBMET01513 | |
| 0.015 | 0.078 | 0.033 | G protein-coupled receptor agonist | 0.033 0.032 DBMET01513 | DBMET01513 | |
| 0.019 | 0.082 | 0.036 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.036 0.021 DBMET01513 | DBMET01513 | |
| 0.028 | 0.092 | 0.06 | Glutamate (mGluR1) antagonist | 0.06 0.039 DBMET01513 | DBMET01513 | |
| 0.024 | 0.088 | 0.078 | Leukocyte elastase inhibitor | 0.044 0.028 DBMET00328 0.078 0.013 DBMET01513 | DBMET01513 | |
| 0.007 | 0.072 | 0.022 | Prostaglandin E2 agonist | 0.022 0.018 DBMET01513 | DBMET01513 | |
| 0.019 | 0.083 | 0.033 | Inosine monophosphate dehydrogenase inhibitor | 0.033 0.029 DBMET01513 | DBMET01513 | |
| 0.052 | 0.117 | 0.087 | Myeloperoxidase inhibitor | 0.087 0.053 DBMET01513 0.085 0.057 DBMET00137 | DBMET01513 | |
| 0.033 | 0.098 | 0.053 | Leukotriene B4 antagonist | 0.053 0.039 DBMET01513 | DBMET01513 | |
| 0.013 | 0.079 | 0.056 | Kainate receptor 2 antagonist | 0.056 0.013 DBMET01513 0.033 0.028 DBMET00137 | DBMET01513 | |
| 0.016 | 0.082 | 0.047 | Carbonic anhydrase IV inhibitor | 0.047 0.027 DBMET01513 | DBMET01513 | |
| 0.05 | 0.116 | 0.061 | Beta 2 adrenoreceptor agonist | 0.061 0.046 DBMET01513 0.059 0.054 DBMET00137 | DBMET01513 | |
| 0.1 | 0.166 | 0.197 | Thiol protease inhibitor | 0.197 0.04 DBMET00328 0.156 0.063 DBMET01513 0.13 0.097 DBMET00137 | DBMET00328 | |
| 0.174 | 0.24 | 0.311 | Interleukin 2 agonist | 0.311 0.066 DBMET01513 | DBMET01513 | |
| 0.014 | 0.081 | 0.031 | LFA antagonist | 0.031 0.014 DBMET01513 | DBMET01513 | |
| 0.144 | 0.211 | 0.21 | Lipoxygenase inhibitor | 0.21 0.13 DBMET01513 | DBMET01513 | |
| 0.025 | 0.093 | 0.13 | Xanthine dehydrogenase inhibitor | 0.13 0.009 DBMET00328 0.057 0.041 DBMET01513 | DBMET00328 | |
| 0.013 | 0.081 | 0.031 | Peroxisome proliferator-activated receptor delta agonist | 0.031 0.027 DBMET01513 | DBMET01513 | |
| 0.104 | 0.172 | 0.234 | DNA methyltransferase I inhibitor | 0.234 0.054 DBMET01513 0.139 0.117 DBMET00137 | DBMET01513 | |
| 0.04 | 0.11 | 0.072 | Heat shock protein 90 beta antagonist | 0.072 0.027 DBMET01513 | DBMET01513 | |
| 0.066 | 0.136 | 0.082 | Protein kinase C zeta inhibitor | 0.082 0.081 DBMET00137 | DBMET00137 | |
| 0.012 | 0.082 | 0.031 | Sirtuin 2 inhibitor | 0.031 0.024 DBMET01513 | DBMET01513 | |
| 0.11 | 0.18 | 0.175 | I kappa B kinase epsilon inhibitor | 0.159 0.11 DBMET01513 0.175 0.094 DBMET00137 | DBMET00137 | |
| 0.018 | 0.09 | 0.045 | Carbonic anhydrase VII inhibitor | 0.045 0.034 DBMET01513 | DBMET01513 | |
| 0.081 | 0.152 | 0.169 | NADPH oxidase inhibitor | 0.169 0.045 DBMET00328 0.149 0.055 DBMET01513 | DBMET00328 | |
| 0.065 | 0.138 | 0.118 | Nitric-oxide synthase inhibitor | 0.118 0.039 DBMET01513 | DBMET01513 | |
| 0.112 | 0.186 | 0.253 | Non-steroidal antiinflammatory agent | 0.198 0.073 DBMET00328 0.253 0.042 DBMET01513 | DBMET01513 | |
| 0.066 | 0.139 | 0.122 | GABA receptor agonist | 0.122 0.055 DBMET01513 | DBMET01513 | |
| 0.051 | 0.126 | 0.076 | Peroxisome proliferator-activated receptor gamma antagonist | 0.076 0.039 DBMET01513 | DBMET01513 | |
| 0.032 | 0.107 | 0.053 | Nicotinic receptor alpha7 subunit antagonist | 0.053 0.039 DBMET01513 | DBMET01513 | |
| 0.021 | 0.097 | 0.043 | Sphingosine 1-phosphate receptor 1 agonist | 0.043 0.028 DBMET01513 | DBMET01513 | |
| 0.022 | 0.099 | 0.039 | Liver X receptor alpha agonist | 0.039 0.031 DBMET01513 | DBMET01513 | |
| 0.023 | 0.1 | 0.057 | Aromatase inhibitor | 0.057 0.043 DBMET01513 | DBMET01513 | |
| 0.049 | 0.126 | 0.069 | Adenosine A3 receptor antagonist | 0.069 0.06 DBMET01513 | DBMET01513 | |
| 0.045 | 0.123 | 0.088 | Calcium channel L-type blocker | 0.088 0.032 DBMET01513 | DBMET01513 | |
| 0.099 | 0.178 | 0.132 | Neuropeptide Y1 antagonist | 0.124 0.115 DBMET00328 0.132 0.095 DBMET01513 0.126 0.108 DBMET00137 | DBMET01513 | |
| 0.004 | 0.084 | 0.021 | Kainate receptor 1 antagonist | 0.021 0.015 DBMET01513 | DBMET01513 | |
| 0.112 | 0.192 | 0.237 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.237 0.082 DBMET01513 0.161 0.13 DBMET00137 | DBMET01513 | |
| 0.027 | 0.11 | 0.049 | Beta 1 adrenoreceptor antagonist | 0.049 0.048 DBMET01513 | DBMET01513 | |
| 0.027 | 0.109 | 0.071 | NMDA 2C receptor antagonist | 0.071 0.032 DBMET01513 | DBMET01513 | |
| 0.046 | 0.132 | 0.105 | Potassium channel (Ca-activated) activator | 0.105 0.051 DBMET01513 | DBMET01513 | |
| 0.042 | 0.13 | 0.069 | Epoxide hydrolase inhibitor | 0.069 0.054 DBMET01513 | DBMET01513 | |
| 0.015 | 0.103 | 0.031 | Carnitine palmitoyltransferase 1 inhibitor | 0.031 0.029 DBMET01513 | DBMET01513 | |
| 0.14 | 0.228 | 0.273 | Transcription factor STAT3 inhibitor | 0.218 0.113 DBMET00328 0.273 0.068 DBMET01513 0.184 0.158 DBMET00137 | DBMET01513 | |
| 0.037 | 0.126 | 0.063 | Beta adrenoreceptor antagonist | 0.063 0.051 DBMET01513 | DBMET01513 | |
| 0.105 | 0.195 | 0.162 | Antipruritic | 0.162 0.081 DBMET01513 | DBMET01513 | |
| 0.021 | 0.111 | 0.044 | NMDA receptor subunit 3B antagonist | 0.044 0.03 DBMET01513 | DBMET01513 | |
| 0.024 | 0.114 | 0.062 | Cathepsin L inhibitor | 0.062 0.036 DBMET00328 | DBMET00328 | |
| 0.101 | 0.192 | 0.228 | DNA methylase inhibitor | 0.228 0.062 DBMET01513 0.136 0.131 DBMET00137 | DBMET01513 | |
| 0.065 | 0.156 | 0.101 | AMP-activated protein kinase stimulant | 0.101 0.069 DBMET01513 | DBMET01513 | |
| 0.009 | 0.101 | 0.032 | AMPA 3 receptor antagonist | 0.032 0.019 DBMET01513 | DBMET01513 | |
| 0.014 | 0.106 | 0.031 | Carnitine palmitoyltransferase inhibitor | 0.031 0.029 DBMET01513 | DBMET01513 | |
| 0.052 | 0.145 | 0.131 | Mediator release inhibitor | 0.131 0.039 DBMET01513 | DBMET01513 | |
| 0.021 | 0.115 | 0.043 | Sphingosine 1-phosphate receptor agonist | 0.043 0.033 DBMET01513 | DBMET01513 | |
| 0.015 | 0.11 | 0.036 | NMDA receptor subunit 3A antagonist | 0.036 0.029 DBMET01513 | DBMET01513 | |
| 0.075 | 0.173 | 0.105 | Nav1.2 sodium channel blocker | 0.105 0.103 DBMET01513 | DBMET01513 | |
| 0.012 | 0.113 | 0.047 | Kainate receptor antagonist | 0.047 0.024 DBMET01513 | DBMET01513 | |
| 0.093 | 0.194 | 0.154 | Hemostatic | 0.154 0.063 DBMET01513 | DBMET01513 | |
| 0.035 | 0.138 | 0.055 | Sphingosine 1-phosphate receptor 1 antagonist | 0.055 0.039 DBMET01513 | DBMET01513 | |
| 0.029 | 0.134 | 0.065 | Leukotriene antagonist | 0.065 0.045 DBMET01513 | DBMET01513 | |
| 0.015 | 0.122 | 0.05 | Carbonic anhydrase I inhibitor | 0.05 0.043 DBMET01513 | DBMET01513 | |
| 0.003 | 0.11 | 0.015 | Immunosuppressant Cyclosporine-like | 0.015 0.005 DBMET00328 0.012 0.008 DBMET01513 | DBMET00328 | |
| 0.01 | 0.118 | 0.04 | Cathepsin L1 inhibitor | 0.04 0.027 DBMET00328 | DBMET00328 | |
| 0.087 | 0.197 | 0.125 | Cyclin-dependent kinase 8 inhibitor | 0.125 0.11 DBMET00137 | DBMET00137 | |
| 0.024 | 0.134 | 0.057 | Diacylglycerol O-acyltransferase inhibitor | 0.057 0.028 DBMET01513 | DBMET01513 | |
| 0.104 | 0.217 | 0.15 | Focal adhesion kinase 2 inhibitor | 0.147 0.136 DBMET01513 0.15 0.131 DBMET00137 | DBMET00137 | |
| 0.092 | 0.21 | 0.166 | MAP kinase kinase 2 inhibitor | 0.147 0.124 DBMET01513 0.166 0.107 DBMET00137 | DBMET00137 | |
| 0.014 | 0.136 | 0.046 | NMDA 2A receptor antagonist | 0.046 0.042 DBMET01513 | DBMET01513 | |
| 0.127 | 0.249 | 0.216 | 12-Lipoxygenase inhibitor | 0.216 0.135 DBMET01513 | DBMET01513 | |
| 0.037 | 0.161 | 0.053 | Adenine nucleotide translocase inhibitor | 0.053 0.045 DBMET01513 | DBMET01513 | |
| 0.045 | 0.172 | 0.08 | Potassium channel activator | 0.08 0.075 DBMET01513 | DBMET01513 | |
| 0.023 | 0.158 | 0.087 | TRPA1 antagonist | 0.087 0.022 DBMET00328 0.058 0.046 DBMET01513 | DBMET00328 | |
| 0.045 | 0.18 | 0.078 | Sphingosine 1-phosphate receptor antagonist | 0.078 0.05 DBMET01513 | DBMET01513 | |
| 0.063 | 0.199 | 0.113 | Toll-Like receptor 9 antagonist | 0.113 0.093 DBMET01513 | DBMET01513 | |
| 0.134 | 0.274 | 0.273 | Transcription factor STAT inhibitor | 0.198 0.141 DBMET00328 0.273 0.072 DBMET01513 | DBMET01513 | |
| 0.066 | 0.211 | 0.119 | Toll-Like receptor antagonist | 0.119 0.087 DBMET01513 | DBMET01513 | |
| 0.022 | 0.17 | 0.065 | Prostaglandin-E synthase inhibitor | 0.065 0.055 DBMET01513 | DBMET01513 | |
| 0.065 | 0.22 | 0.208 | Angiogenesis stimulant | 0.208 0.091 DBMET01513 | DBMET01513 | |
| 0.051 | 0.206 | 0.103 | Nav1.3 sodium channel blocker | 0.1 0.097 DBMET00328 0.103 0.094 DBMET01513 | DBMET01513 | |
| 0.059 | 0.242 | 0.114 | Calcium channel blocker | 0.114 0.094 DBMET01513 | DBMET01513 | |
| 0.02 | 0.221 | 0.067 | Glutamate receptor agonist | 0.067 0.066 DBMET01513 | DBMET01513 | |
| 0.159 | 0.364 | 0.335 | Calcium channel L-type activator | 0.335 0.129 DBMET01513 | DBMET01513 | |
| 0.084 | 0.292 | 0.205 | Antioxidant | 0.205 0.11 DBMET01513 | DBMET01513 | |
| 0.064 | 0.271 | 0.123 | Heat shock protein 90 antagonist | 0.123 0.109 DBMET01513 | DBMET01513 | |
| 0.066 | 0.276 | 0.131 | Heat shock protein 90 alpha antagonist | 0.124 0.12 DBMET00328 0.131 0.11 DBMET01513 | DBMET01513 | |
| 0.051 | 0.266 | 0.11 | Cytokine production inhibitor | 0.11 0.1 DBMET01513 | DBMET01513 | |
| 0.046 | 0.264 | 0.086 | Interleukin 5 antagonist | 0.086 0.061 DBMET00328 | DBMET00328 | |
| 0.049 | 0.268 | 0.139 | Toll-Like receptor 4 antagonist | 0.139 0.028 DBMET01513 | DBMET01513 | |
| 0.03 | 0.289 | 0.111 | ATPase (Vacuolar H+) inhibitor | 0.111 0.027 DBMET01513 | DBMET01513 | |
| 0.017 | 0.292 | 0.074 | Leukotriene synthesis inhibitor | 0.074 0.041 DBMET01513 | DBMET01513 | |
| 0.011 | 0.29 | 0.036 | Retinoic acid alpha receptor agonist | 0.036 0.033 DBMET01513 | DBMET01513 | |
| 0.014 | 0.294 | 0.079 | Elastase 3B inhibitor | 0.031 0.02 DBMET00328 0.079 0.002 DBMET01513 | DBMET01513 | |
| 0.014 | 0.294 | 0.079 | Elastase 2B inhibitor | 0.031 0.02 DBMET00328 0.079 0.002 DBMET01513 | DBMET01513 | |
| 0.014 | 0.294 | 0.079 | Elastase 3A inhibitor | 0.031 0.02 DBMET00328 0.079 0.002 DBMET01513 | DBMET01513 | |
| 0.017 | 0.312 | 0.095 | Nitric oxide donor | 0.095 0.011 DBMET01513 | DBMET01513 | |
| 0.055 | 0.396 | 0.23 | Hepatoprotectant | 0.23 0.05 DBMET01513 | DBMET01513 | |
| 0.068 | 0.43 | 0.386 | Lipocortins synthesis antagonist | 0.386 0.01 DBMET01513 | DBMET01513 | |
| 0.005 | 0.377 | 0.069 | Elastase 2 inhibitor | 0.021 0.016 DBMET00328 0.069 0.004 DBMET01513 | DBMET01513 | |
| 0.005 | 0.377 | 0.069 | Elastase 2A inhibitor | 0.021 0.016 DBMET00328 0.069 0.004 DBMET01513 | DBMET01513 | |
| 0.003 | 0.421 | 0.025 | Retinoid X beta receptor agonist | 0.025 0.011 DBMET01513 | DBMET01513 | |
| 0.036 | 0.455 | 0.183 | Free radical scavenger | 0.183 0.112 DBMET01513 | DBMET01513 | |
| 0.003 | 0.457 | 0.059 | Squalene synthetase inhibitor | 0.059 0.012 DBMET01513 | DBMET01513 | |
| 0.003 | 0.47 | 0.029 | Retinoid X gamma receptor agonist | 0.029 0.011 DBMET01513 | DBMET01513 | |
| 0.007 | 0.478 | 0.038 | Caspase 6 inhibitor | 0.038 0.009 DBMET00328 | DBMET00328 | |
| 0.004 | 0.482 | 0.03 | Retinoid X gamma receptor antagonist | 0.03 0.012 DBMET01513 | DBMET01513 | |
| 0.069 | 0.567 | 0.29 | Apoptosis agonist | 0.29 0.179 DBMET01513 | DBMET01513 | |
| 0.004 | 0.589 | 0.062 | Prostaglandin EP2 antagonist | 0.062 0.039 DBMET01513 | DBMET01513 | |
| 0.048 | 0.672 | 0.358 | Apoptosis antagonist | 0.358 0.052 DBMET00328 0.338 0.062 DBMET01513 | DBMET00328 | |
| 0.016 | 0.662 | 0.103 | Thioredoxin reductase inhibitor | 0.103 0.026 DBMET00328 0.077 0.071 DBMET01513 | DBMET00328 | |
| 0.007 | 0.664 | 0.084 | CDC25A inhibitor | 0.084 0.039 DBMET01513 | DBMET01513 | |
| 0.017 | 0.678 | 0.069 | DNA helicase inhibitor | 0.069 0.018 DBMET01513 | DBMET01513 | |
| 0.015 | 0.688 | 0.188 | Thioredoxin inhibitor | 0.188 0.009 DBMET01513 | DBMET01513 | |
| 0.009 | 0.728 | 0.13 | Protease inhibitor | 0.13 0.041 DBMET00328 | DBMET00328 | |
| 0.01 | 0.754 | 0.129 | Bone formation stimulant | 0.129 0.077 DBMET01513 | DBMET01513 | |
| 0.011 | 0.802 | 0.053 | Factor III inhibitor | 0.053 0.028 DBMET01513 | DBMET01513 | |
| 0.03 | 0.834 | 0.346 | Sodium/bile acid cotransporter inhibitor | 0.346 0.042 DBMET01513 | DBMET01513 | |
| 0.009 | 0.821 | 0.032 | Calcium-independent phospholipase A2 inhibitor | 0.032 0.03 DBMET01513 | DBMET01513 | |
| 0.013 | 0.826 | 0.202 | Antineoplastic alkaloid | 0.202 0.013 DBMET01513 | DBMET01513 | |
| 0.004 | 0.817 | 0.076 | Peroxisome proliferator-activated receptor gamma agonist | 0.076 0.044 DBMET01513 | DBMET01513 | |
| 0.005 | 0.829 | 0.171 | Lipid peroxidase inhibitor | 0.171 0.055 DBMET01513 | DBMET01513 | |
| 0.003 | 0.828 | 0.039 | HMG CoA reductase inhibitor | 0.039 0.016 DBMET01513 | DBMET01513 | |
| 0.001 | 0.835 | 0.073 | 3C-Like protease (MERS coronavirus) inhibitor | 0.073 0.001 DBMET00328 | DBMET00328 | |
| 0.002 | 0.861 | 0.62 | Calpain 1 inhibitor | 0.62 0.002 DBMET00328 | DBMET00328 | |
| 0.012 | 0.871 | 0.365 | Immunosuppressant | 0.365 0.079 DBMET01513 | DBMET01513 | |
| 0.007 | 0.88 | 0.08 | Falcipain inhibitor | 0.08 0.074 DBMET00328 | DBMET00328 | |
| 0.008 | 0.881 | 0.042 | Glutamate (mGluR8) antagonist | 0.042 0.014 DBMET01513 | DBMET01513 | |
| 0.003 | 0.878 | 0.046 | Aldose reductase inhibitor | 0.046 0.043 DBMET01513 | DBMET01513 | |
| 0.003 | 0.898 | 0.063 | HIV-1 integrase (3'-Processing) inhibitor | 0.063 0.044 DBMET01513 | DBMET01513 | |
| 0.005 | 0.903 | 0.228 | Vasodilator | 0.228 0.084 DBMET01513 | DBMET01513 | |
| 0.023 | 0.929 | 0.534 | Factor V inhibitor | 0.534 0.001 DBMET00328 | DBMET00328 | |
| 0.008 | 0.926 | 0.138 | Farnesoid X receptor antagonist | 0.138 0.069 DBMET01513 | DBMET01513 | |
| 0.003 | 0.932 | 0.089 | HIV-1 integrase (Strand Transfer) inhibitor | 0.089 0.027 DBMET01513 | DBMET01513 | |
| 0.021 | 0.956 | 0.4 | Growth hormone agonist | 0.4 0.016 DBMET01513 | DBMET01513 | |
| 0.005 | 0.945 | 0.06 | Transcription factor AP-1 inhibitor | 0.06 0.046 DBMET01513 | DBMET01513 | |
| 0.006 | 0.962 | 0.188 | Elastase 1 inhibitor | 0.12 0.012 DBMET00328 0.188 0.004 DBMET01513 | DBMET01513 | |
| 0.01 | 0.966 | 0.142 | Interleukin 4 antagonist | 0.142 0.058 DBMET01513 | DBMET01513 | |
| 0.013 | 0.971 | 0.198 | ABCA1 expression enhancer | 0.198 0.009 DBMET00328 0.122 0.029 DBMET01513 | DBMET00328 | |
| 0.003 | 0.962 | 0.093 | CDC25B inhibitor | 0.093 0.019 DBMET00328 0.06 0.05 DBMET01513 | DBMET00328 | |
| 0.004 | 0.968 | 0.053 | Human rhinovirus A protease inhibitor | 0.053 0.04 DBMET00328 | DBMET00328 | |
| 0.005 | 0.969 | 0.264 | Platelet adhesion inhibitor | 0.264 0.045 DBMET01513 | DBMET01513 | |
| 0.011 | 0.98 | 0.078 | Ca(v)3.1 blocker | 0.078 0.065 DBMET00328 | DBMET00328 | |
| 0.002 | 0.973 | 0.044 | Benzodiazepine receptor peripheral-type antagonist | 0.044 0.01 DBMET01513 | DBMET01513 | |
| 0.009 | 0.99 | 0.372 | Caspase 3 stimulant | 0.372 0.052 DBMET00328 0.215 0.149 DBMET01513 | DBMET00328 | |
| 0.002 | 0.986 | 0.035 | Trypsin II inhibitor | 0.035 0.016 DBMET00328 | DBMET00328 | |
| 0.003 | 0.988 | 0.107 | Cyclooxygenase 1 inhibitor | 0.107 0.092 DBMET01513 | DBMET01513 | |
| 0.003 | 0.988 | 0.107 | Lipase inhibitor | 0.107 0.024 DBMET00328 | DBMET00328 | |
| 0.006 | 0.992 | 0.211 | Caspase 9 inhibitor | 0.211 0.004 DBMET00328 0.075 0.027 DBMET01513 | DBMET00328 | |
| 0.004 | 0.99 | 0.159 | Thrombolytic | 0.159 0.075 DBMET01513 | DBMET01513 | |
| 0.004 | 0.991 | 0.106 | Cell adhesion inhibitor | 0.106 0.079 DBMET01513 | DBMET01513 | |
| 0.004 | 0.991 | 0.108 | Chelator | 0.108 0.066 DBMET01513 | DBMET01513 | |
| 0.007 | 0.995 | 0.448 | 3C-Like protease (SARS coronavirus) inhibitor | 0.448 0.002 DBMET00328 0.083 0.061 DBMET01513 | DBMET00328 | |
| 0.003 | 0.991 | 0.128 | Neurotrophic factor | 0.128 0.083 DBMET00328 | DBMET00328 | |
| 0.002 | 0.991 | 0.052 | Angiotensin-converting enzyme inhibitor | 0.052 0.042 DBMET01513 | DBMET01513 | |
| 0.004 | 0.994 | 0.135 | Chymotrypsin inhibitor | 0.135 0.021 DBMET00328 | DBMET00328 | |
| 0.004 | 0.994 | 0.132 | Insulin secretagoues | 0.132 0.094 DBMET01513 | DBMET01513 | |
| 0.003 | 0.994 | 0.122 | Factor XII inhibitor | 0.122 0.023 DBMET00328 | DBMET00328 | |
| 0.004 | 0.996 | 0.036 | Integrin alpha1beta1 antagonist | 0.036 0.033 DBMET01513 | DBMET01513 | |
| 0.003 | 0.995 | 0.159 | Amyloid beta precursor protein antagonist | 0.159 0.092 DBMET00328 | DBMET00328 | |
| 0.003 | 0.995 | 0.088 | Elastase inhibitor | 0.088 0.013 DBMET01513 | DBMET01513 | |
| 0.003 | 0.995 | 0.5 | Cathepsin B inhibitor | 0.5 0.003 DBMET00328 | DBMET00328 | |
| 0.002 | 0.996 | 0.101 | Thrombin inhibitor | 0.101 0.025 DBMET00328 | DBMET00328 | |
| 0.002 | 0.996 | 0.105 | Cathepsin K inhibitor | 0.105 0.005 DBMET00328 | DBMET00328 | |
| 0.002 | 0.996 | 0.096 | Plasminogen activator inhibitor | 0.096 0.018 DBMET00328 | DBMET00328 | |
| 0.002 | 0.997 | 0.083 | Trypsin inhibitor | 0.083 0.025 DBMET00328 | DBMET00328 | |
| 0.001 | 0.996 | 0.188 | Plasmin inhibitor | 0.188 0.007 DBMET00328 | DBMET00328 | |
| 0.001 | 0.997 | 0.029 | Trypsin I inhibitor | 0.029 0.027 DBMET00328 | DBMET00328 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |